{"gene":"TRAF5","run_date":"2026-06-10T10:51:55","timeline":{"discoveries":[{"year":1996,"finding":"TRAF5 was identified as a novel TRAF family member containing RING finger, zinc finger, coiled-coil, and TRAF homology domains. In vitro translation and co-immunoprecipitation in COS7 cells showed TRAF5 binds the cytoplasmic region of the lymphotoxin-beta receptor (LT-βR) but not CD40, both TNF receptors, Fas, or NGF receptor. Overexpression of full-length TRAF5 (but not a truncated form lacking the zinc-binding region) activated NF-κB in HEK293 cells, and dominant-negative TRAF5 partially inhibited LT-βR-induced NF-κB activation.","method":"In vitro binding assay (translated protein), co-immunoprecipitation in COS7 cells, NF-κB reporter assay in HEK293 cells, domain truncation analysis","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — multiple orthogonal methods (in vitro binding, Co-IP, reporter assay, domain mutagenesis), foundational paper replicated by subsequent work","pmids":["8663299"],"is_preprint":false},{"year":1996,"finding":"TRAF5 was cloned via yeast two-hybrid using the CD40 cytoplasmic tail as bait. In vitro binding assays confirmed TRAF5 associates with CD40 (residues 230–269 required) but not TNFR2. Overexpression of TRAF5 activates NF-κB, and amino-terminally truncated TRAF5 suppresses CD40-mediated CD23 induction, similar to TRAF3.","method":"Yeast two-hybrid, in vitro binding assay, NF-κB reporter assay, CD40 deletion mutant analysis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — yeast two-hybrid plus in vitro binding plus functional reporter, corroborated by independent lab (PMID 8663299)","pmids":["8790348"],"is_preprint":false},{"year":1997,"finding":"Human TRAF5 cDNA was cloned and mapped to chromosome 1q32. The encoded 557-aa protein retains typical TRAF family structural features. Overexpression of human TRAF5 activated NF-κB in 293T cells, and the protein was found to bind LT-βR cytoplasmic region more efficiently than CD40 or CD30.","method":"cDNA cloning, chromosomal mapping (FISH), NF-κB reporter assay, binding assay","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reporter assay and binding data consistent with founding papers; single lab","pmids":["9177772"],"is_preprint":false},{"year":1997,"finding":"The novel TNFR family member ATAR (both human and mouse) physically interacts with TRAF5 and TRAF2 via its C-terminal 20 amino acids. Co-expression of ATAR with TRAF5 (but not TRAF2) results in synergistic NF-κB activation, indicating differential roles of TRAF2 and TRAF5 downstream of ATAR.","method":"In vitro binding assay, co-immunoprecipitation, NF-κB reporter assay","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and reporter assay, single lab, two complementary methods","pmids":["9153189"],"is_preprint":false},{"year":1998,"finding":"CD27 activates NF-κB and SAPK/JNK through direct interaction with TRAF2 and TRAF5 via its C-terminal PIQEDYR motif. Dominant-negative TRAF2 or TRAF5 blocked both NF-κB and SAPK/JNK activation induced by CD27. NF-κB-inducing kinase (NIK) acts as a common downstream kinase of TRAF2 and TRAF5 in this pathway.","method":"Cytoplasmic domain deletion analysis, dominant-negative transfection, NF-κB EMSA, kinase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — epistasis established by dominant-negatives plus deletion mapping, replicated in multiple cell types, subsequently confirmed by KO mice (PMID 10449775)","pmids":["9582383"],"is_preprint":false},{"year":1998,"finding":"OX40 associates with TRAF1, TRAF2, TRAF3, and TRAF5 (but not TRAF4) in vitro, and with TRAF2, TRAF3, and TRAF5 in vivo. A cytoplasmic sequence (aa 256–263, GGSFRTPI) is required for TRAF association and NF-κB activation. Dominant-negative TRAF2 and TRAF5 suppress OX40-induced NF-κB activation in a dose-dependent manner.","method":"GST pull-down, co-immunoprecipitation in HEK293T, NF-κB EMSA, deletion mutant analysis, dominant-negative transfection","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — GST pull-down, reciprocal Co-IP, and functional epistasis with dominant negatives, multiple orthogonal methods","pmids":["9488716"],"is_preprint":false},{"year":1998,"finding":"Human TRAF5 protein binds the LT-βR cytoplasmic region more efficiently than CD40 or CD30, and overexpression activates NF-κB in 293T cells. The gene was mapped to human chromosome 1q32.3–q41.1.","method":"cDNA cloning, binding assay, NF-κB reporter assay, chromosomal mapping (PCR-RFLP)","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — binding assay and reporter assay, confirmatory of earlier papers, single lab","pmids":["9511754"],"is_preprint":false},{"year":1999,"finding":"TRAF5-deficient mice generated by gene targeting showed that TRAF5 loss does not completely abrogate TNF-, CD27-, or CD40-induced NF-κB or JNK activation, but TRAF5-/- B cells exhibit defects in CD40-driven proliferation, upregulation of CD23, CD54, CD80, CD86, and Fas, and reduced IgG production with IL-4. TRAF5-/- T cells show impaired CD27-mediated costimulatory signaling.","method":"Gene targeting (KO mice), NF-κB EMSA, JNK kinase assay, flow cytometry, in vitro Ig production assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic KO with multiple defined cellular phenotypes and signaling readouts, replicated across lymphocyte subsets","pmids":["10449775"],"is_preprint":false},{"year":2001,"finding":"TRAF2 and TRAF5 double knockout (DKO) MEFs show severely impaired TNF-induced (but not IL-1-induced) NF-κB nuclear translocation, establishing redundant roles for TRAF2 and TRAF5 specifically in TNF-induced NF-κB activation. DKO MEFs are more susceptible to TNF-induced cytotoxicity than TRAF2 single KO cells.","method":"Double knockout mouse embryonic fibroblasts, NF-κB nuclear translocation assay, cytotoxicity assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis via double KO, multiple signaling and viability readouts, clean mechanistic separation from IL-1 pathway","pmids":["11479302"],"is_preprint":false},{"year":2001,"finding":"Overexpression of TRAF5 (and TRAF6), or LMP1 (via its TRAF-binding site), suppresses Epstein-Barr virus oriP replication through a p38 MAPK-dependent pathway. Dominant-negative TRAF5 and TRAF6 relieve LMP1-induced oriP suppression; p38 MAPK inhibition abolishes the suppressive effect.","method":"Transient replication assay, dominant-negative transfection, p38 MAPK inhibitor, LMP1 deletion mutant analysis","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional epistasis with dominant negatives and pharmacological inhibitor, single lab","pmids":["11333886"],"is_preprint":false},{"year":2002,"finding":"In Hodgkin-Reed-Sternberg (H-RS) cells with constitutively active CD30 signaling, TRAF2 and TRAF5 aggregate in cytoplasmic clusters and co-localize with IKKα, NIK, and IκBα. Dominant-negative TRAF2 and TRAF5 suppressed cytoplasmic aggregation and constitutive NF-κB activation, suggesting TRAF5 functions as a scaffolding protein in CD30-driven NF-κB signaling.","method":"Confocal immunofluorescence microscopy, dominant-negative transfection, NF-κB assay","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2–3 / Moderate — direct localization by confocal microscopy with functional consequence (dominant-negative rescue), single lab","pmids":["12000717"],"is_preprint":false},{"year":2003,"finding":"TNF-α-induced phosphorylation of NF-κB p65 on Ser-536 is mediated through a TRAF2/TRAF5–TAK1–IKK pathway. This phosphorylation is severely impaired in MEFs from traf2-/-traf5-/- double KO mice. Dominant-negative TAK1, IKKα, IKKβ, and siRNAs against TAK1, IKKα, IKKβ each blocked the phosphorylation.","method":"Anti-phospho-p65 (Ser-536) antibody, double KO MEFs, dominant-negative overexpression, siRNA knockdown","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic (DKO MEFs), siRNA, and dominant-negative approaches in combination; multiple orthogonal methods establishing pathway position","pmids":["12842894"],"is_preprint":false},{"year":2003,"finding":"TRAF5-deficient osteoclast progenitor cells fail to differentiate effectively into mature multinucleated osteoclasts in response to RANKL or TNFα, even though JNK and NF-κB activation is preserved, demonstrating TRAF5 is required for osteoclastogenesis downstream of or parallel to these signaling events. In vivo, PTH-induced hypercalcemia is delayed in TRAF5-deficient mice.","method":"TRAF5-deficient mouse osteoclast progenitor cultures, RANKL/TNFα stimulation, JNK/NF-κB activation assay, PTH hypercalcemia model","journal":"Journal of bone and mineral research","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO mouse cells with defined osteoclast differentiation phenotype, in vivo PTH model, multiple readouts","pmids":["12619928"],"is_preprint":false},{"year":2009,"finding":"TRAF5 associates strongly with Epstein-Barr virus latent membrane protein 1 (LMP1) — more strongly than with CD40 — and is required for LMP1-mediated c-Jun kinase signaling and B cell hyperactivation phenotypes. In mice expressing LMP1 in place of CD40, TRAF5 deficiency abrogated much of the abnormal splenic phenotype (splenomegaly, lymphadenopathy, elevated IL-6, autoantibodies).","method":"Co-immunoprecipitation, LMP1/CD40 transgenic mice crossed with TRAF5-KO mice, JNK assay, in vivo phenotyping","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vitro Co-IP combined with in vivo genetic epistasis in transgenic/KO mice, multiple phenotypic readouts","pmids":["19805155"],"is_preprint":false},{"year":2009,"finding":"In TRAF2/TRAF5 double KO (T2/5 DKO) cells, basal IKK activity and NF-κB-dependent gene expression are elevated (not reduced) due to elevated NIK activity. TNFα-induced RIP1 ubiquitination is impaired in DKO cells, yet TNFα can still further activate IKK. TRAF2 (not TRAF5) is required for recruiting anti-apoptotic proteins to TNFR1 complex and protecting against TNFα-induced cell death.","method":"DKO MEF cells, IKK kinase assay, NF-κB target gene expression, NIK inhibition, TNFR1 complex immunoprecipitation, cytotoxicity assay","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple signaling assays in DKO cells plus rescue experiments; mechanistically refines the DKO phenotype reported by earlier studies","pmids":["19409903"],"is_preprint":false},{"year":2010,"finding":"TRAF5 is a downstream effector of MAVS in antiviral innate immune signaling. The MAVS transmembrane domain mediates dimerization and subsequent association with TRAF5 and induction of TRAF5 ubiquitination in a CARD-dependent manner. TRAF5 mediates both IRF3 and NF-κB activation downstream of MAVS, and NEMO is recruited to dimerized MAVS in a TRAF3/TRAF5-dependent manner.","method":"Co-immunoprecipitation, ubiquitination assay, IRF3/NF-κB reporter assays, MAVS domain truncation, siRNA knockdown of TRAF5","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination assay, and reporter assays; single lab, multiple complementary methods","pmids":["20161788"],"is_preprint":false},{"year":2010,"finding":"TRAF5 deficiency in mice accelerates atherosclerosis: TRAF5-/-/LDLR-/- mice develop larger lesions with more lipids and macrophages. TRAF5 deficiency in endothelial cells or leukocytes enhances inflammatory cell adhesion and increases JNK activation, and TRAF5-deficient macrophages show enhanced foam cell formation. These effects appear independent of TRAF2.","method":"TRAF5/LDLR double KO mice on high-cholesterol diet, intravital microscopy, dynamic adhesion assays, foam cell lipid uptake assay, JNK activation measurement","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — in vivo KO mouse model with intravital microscopy plus in vitro mechanistic assays, multiple orthogonal methods","pmids":["20651286"],"is_preprint":false},{"year":2011,"finding":"IL-17 stabilizes CXCL1 mRNA via a pathway involving Act1→TRAF2/TRAF5→SF2(ASF). TRAF2 and TRAF5 are necessary for IL-17-induced mRNA stabilization. IL-17 promotes formation of a TRAF5–TRAF2–Act1–SF2(ASF) complex; SF2(ASF) binding to CXCL1 mRNA is reduced after IL-17 stimulation, correlating with mRNA stabilization.","method":"siRNA knockdown, mRNA half-life assay, co-immunoprecipitation, RNA-protein binding assay","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — siRNA epistasis establishing pathway order, Co-IP of complex, mRNA half-life measurement, multiple orthogonal approaches in one study","pmids":["21822258"],"is_preprint":false},{"year":2012,"finding":"Numbl directly interacts with TRAF5 and promotes K48-linked polyubiquitination of TRAF5, committing it to proteasomal degradation, thereby dampening TRAF5-dependent NF-κB activation and inhibiting glioma cell migration and invasion.","method":"Co-immunoprecipitation, ubiquitination assay (K48-specific), proteasome inhibitor treatment, overexpression/knockdown of Numbl, NF-κB reporter, migration/invasion assays","journal":"Molecular biology of the cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, ubiquitination linkage characterization, and functional rescue; single lab","pmids":["22593207"],"is_preprint":false},{"year":2012,"finding":"Crystal structures of the TRAF domain of TRAF5 and TRAF3 (bound to a Cardif/MAVS TRAF-interacting motif peptide) were solved. Structural comparison identified two key residues in TRAF3 (Tyr440 and Phe473) near the Cardif binding pocket absent in TRAF5. Mutating the corresponding TRAF5 residues to match TRAF3 conferred TRAF3-like antiviral (IFN-inducing) activity on TRAF5.","method":"X-ray crystallography, in vitro binding assay, cellular IFN reporter assay, site-directed mutagenesis","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure plus mutagenesis plus functional in vitro and cellular assays; rigorous multi-method single study","pmids":["23150880"],"is_preprint":false},{"year":2013,"finding":"TRAF5 is a negative regulator of TLR signaling in B lymphocytes. TRAF5-/- B cells overproduce IL-6, IL-12p40, IL-10, TNF-α, and IgM upon TLR stimulation, with markedly enhanced phosphorylation of ERK1/2 and JNK but no effect on NF-κB or cell survival. Following TLR stimulation, TRAF5 associates with MyD88 and TAB2, and negatively regulates TAB2–TRAF6 association.","method":"TRAF5 KO B cells, cytokine ELISA, flow cytometry, phospho-MAPK western blot, co-immunoprecipitation (TRAF5 with MyD88/TAB2/TRAF6)","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — KO cells with multiple cytokine and signaling readouts, Co-IP establishing molecular mechanism, cell-type specificity confirmed","pmids":["24259503"],"is_preprint":false},{"year":2014,"finding":"TRAF5 constitutively associates with a cytoplasmic region of gp130 that overlaps the STAT3 binding site, suppressing STAT3 recruitment and activation in response to IL-6, thereby limiting Th17 differentiation. TRAF5-deficient naïve CD4+ T cells show enhanced Th17 differentiation and TH17-driven EAE is greatly exacerbated in Traf5-/- mice.","method":"Co-immunoprecipitation (TRAF5–gp130), STAT3 phosphorylation assay, Traf5-/- mouse model, Th17 differentiation assay, EAE model","journal":"Nature immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — Co-IP establishing direct gp130 binding, signaling assay, KO mouse with in vivo disease model, multiple orthogonal methods","pmids":["24681564"],"is_preprint":false},{"year":2015,"finding":"TRAF5 directly interacts with RORγt (the Th17 master transcription factor) and promotes K63-linked polyubiquitination of RORγt via its RING finger domain, stabilizing RORγt protein. TRAF5 depletion in Th17 cells destabilizes RORγt and downregulates IL-17A and other Th17-related genes.","method":"Co-immunoprecipitation, ubiquitination assay (K63-specific), RING domain mutant, TRAF5 knockdown in Th17 cells, RORγt protein stability assay, qRT-PCR","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — Co-IP, K63-specific ubiquitination, RING domain mutagenesis, and functional gene expression readout; multiple orthogonal methods in one study","pmids":["26453305"],"is_preprint":false},{"year":2016,"finding":"TRAF5 negatively regulates NAFLD/NASH by blocking JNK1 (but not JNK2) activity. TRAF5 deficiency worsens HFD-induced metabolic disorders, and Jnk1 ablation markedly ameliorates the detrimental effects of Traf5 deficiency on obesity, inflammation, insulin resistance, hepatic steatosis, and fibrosis.","method":"TRAF5 KO and overexpression in mice (HFD and ob/ob models), JNK1/JNK2-selective genetic ablation, liver histology, metabolic parameters","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic epistasis (Traf5-KO × Jnk1-KO), multiple in vivo mouse models, isoform specificity established","pmids":["27032381"],"is_preprint":false},{"year":2016,"finding":"Deep mutational scanning of TRAF2, TRAF3, and TRAF5 MATH domain peptide-binding preferences revealed that TRAF5 shows distinct peptide binding specificity compared to TRAF2 and TRAF3. Different preferences were identified in both CD40 and TANK background peptide libraries, demonstrating previously unappreciated binding selectivity among TRAF paralogs.","method":"Deep mutational scanning, bacterial surface display of peptide libraries, next-generation sequencing enrichment analysis, individual peptide affinity measurement","journal":"Protein science","confidence":"Medium","confidence_rationale":"Tier 1 / Moderate — rigorous in vitro binding screen with mutagenesis, but functional consequences not tested; single lab","pmids":["26779844"],"is_preprint":false},{"year":2018,"finding":"TRAF2 and TRAF5 constitutively bind to gp130 and inhibit IL-6-driven JAK1 transphosphorylation by limiting proximal JAK1–JAK1 interaction in the IL-6 receptor complex. This was demonstrated using a luciferase fragment complementation system for JAK1–JAK1 proximity. Traf5-/- CD4+ T cells display significantly higher IL-6-induced pJAK1 levels than wild-type cells.","method":"Luciferase fragment complementation for JAK1–JAK1 interaction, HEK293T co-transfection, phospho-JAK1 western blot in Traf5-/- T cells","journal":"International immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — bioluminescence complementation for protein proximity plus KO cell validation; single lab, two complementary methods","pmids":["29668931"],"is_preprint":false},{"year":2019,"finding":"TRAF5 promotes plasmacytoid dendritic cell (pDC) development from bone marrow progenitors in a cell-intrinsic manner. TRAF5 regulates the balance of transcription factors TCF4 and ID2 to promote pDC versus conventional DC commitment.","method":"TRAF5-/- mice, bone marrow chimera experiments, flow cytometry of DC subsets, bone marrow progenitor culture, TCF4/ID2 expression analysis","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — cell-intrinsic KO with bone marrow chimeras and defined transcription factor readout; single lab","pmids":["31668809"],"is_preprint":false},{"year":2020,"finding":"14-3-3ζ physically interacts with TRAF5 (and TRAF6), and this interaction is increased in the presence of IL-17A. TRAF5 acts as an endogenous suppressor of IL-17A-induced IL-6 production, and 14-3-3ζ counters TRAF5's suppressive effect. 14-3-3ζ interaction with TRAF proteins is required for IL-17A-induced IL-6 levels, while TRAF5 and TRAF6 define distinct branches (IL-6 vs. CXCL-1) of IL-17A signaling.","method":"Co-immunoprecipitation, genetically manipulated human and mouse cells, ex vivo and in vivo rat models, IL-6/CXCL-1 production assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP and functional KO/KD experiments in multiple models; single lab","pmids":["32968020"],"is_preprint":false},{"year":2020,"finding":"TRAF5 protects against myocardial ischemia/reperfusion injury by promoting AKT activation. TRAF5-knockout mice exhibit heavier heart damage, inflammatory response, and cell death after I/R injury. TRAF5 overexpression in H/R-stimulated cardiomyocytes inhibits inflammation and apoptosis.","method":"TRAF5 KO mice (myocardial I/R model), cardiomyocyte overexpression, AKT phosphorylation assay, apoptosis/inflammation readouts","journal":"European journal of pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse plus cellular overexpression with AKT signaling readout; single lab","pmids":["32234528"],"is_preprint":false},{"year":2020,"finding":"TRAF5 deficiency in nonhematopoietic intestinal epithelial cells reduces TRAF2 protein stability in a proteasome-dependent manner during inflammation, identifying TRAF5 as required for TRAF2 protein maintenance in inflamed colon tissue.","method":"TRAF5 KO mice (DSS colitis model), bone marrow chimeras, TRAF2 protein assay, proteasome inhibitor treatment, proinflammatory cytokine stimulation of TRAF5-/- nonhematopoietic cells","journal":"ImmunoHorizons","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO + chimeras + in vitro proteasome inhibitor; single lab, multiple methods","pmids":["32156688"],"is_preprint":false},{"year":2021,"finding":"TRAF5 deficiency in mice aggravates diet-induced obesity and metabolic derangements. TRAF5-deficient adipocytes (but not leukocytes) show increased expression of TNFα, MIP-1α, MCP-1, and RANTES, identifying TRAF5 as an anti-inflammatory regulator in adipocytes.","method":"Traf5-/- mice on high-fat diet, flow cytometry of adipose stromal vascular fraction, cell-type-specific gene expression, adipocyte isolation","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KO mouse model with cell-type-specific mechanistic resolution; single lab","pmids":["34348490"],"is_preprint":false},{"year":2021,"finding":"TRAF5 silencing in HCC cells enhances necroptosis by suppressing LTBR (lymphotoxin-beta receptor)-mediated NF-κB signaling. Co-immunoprecipitation confirmed interaction between TRAF5 and LTBR. LTBR overexpression abolished the promotive effect of TRAF5 knockdown on necroptosis and reversed NF-κB suppression.","method":"Co-immunoprecipitation (TRAF5–LTBR), siRNA knockdown, LTBR overexpression rescue, NF-κB western blot, necroptosis markers (p-RIP1, p-MLKL), xenograft model","journal":"PeerJ","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, genetic rescue, signaling pathway and necroptosis markers; single lab","pmids":["37366426"],"is_preprint":false},{"year":2023,"finding":"TRAF5 regulates intestinal Th1/Th17 cell differentiation through Runx1. In a T-cell transfer colitis model, TRAF5-/- CD4+ T cells cause more severe colitis with increased IFN-γ, TNF-α, IL-17a. AAV-mediated Runx1 knockout inhibited TRAF5-/- CD4+ T cell differentiation into Th1 and Th17 cells in vivo, placing Runx1 downstream of TRAF5 in this pathway.","method":"T-cell transfer colitis model (Rag2-/- recipients), AAV-mediated Runx1 KO in vivo, flow cytometry, cytokine measurement (ELISA, qRT-PCR, IHC)","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo genetic epistasis (TRAF5-KO + Runx1-KO) with defined T cell phenotype; single lab","pmids":["37575027"],"is_preprint":false},{"year":2024,"finding":"IL-17A promotes formation of a TRAF2/TRAF5/HuR complex that enhances PFKFB3 mRNA stability and expression, thereby activating glycolysis in hepatic stellate cells. Co-IP, RNA immunoprecipitation, and RNA pull-down confirmed interactions among TRAF2, TRAF5, and HuR in this complex. Silencing TRAF2 or TRAF5 abolished IL-17A-induced PFKFB3 upregulation and glycolysis.","method":"Co-immunoprecipitation, RNA immunoprecipitation (RIP), RNA pull-down, siRNA knockdown, glycolysis assay (ECAR), western blot","journal":"Central-European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP, RIP, and RNA pull-down establishing complex, functional rescue experiments; single lab","pmids":["39944257"],"is_preprint":false},{"year":2025,"finding":"The E3 ubiquitin ligase Huwe1 is required for TRAF5 activity in type I IFN induction downstream of RIG-I-like receptors. Proteomics identified TRAF5 (and MAVS and other TRAFs) as putative Huwe1 substrates; TRAF5 physically interacts with Huwe1; and Huwe1 is essential for TRAF5-dependent IFN-β induction.","method":"CRISPR KO of Huwe1, IFN-β reporter assay, proteomics for substrate identification, co-immunoprecipitation (Huwe1–TRAF5), primary macrophages","journal":"bioRxiv","confidence":"Low","confidence_rationale":"Tier 2 / Weak — Co-IP and functional KO data from preprint, single lab, not yet peer-reviewed","pmids":["bio_10.1101_2025.03.27.645708"],"is_preprint":true}],"current_model":"TRAF5 is a cytoplasmic adaptor and E3 ubiquitin ligase that is recruited to multiple TNF receptor superfamily members (LT-βR, CD40, CD27, OX40, TNFR1/2) and to cytokine receptors (gp130/IL-6R), where it acts redundantly with TRAF2 to activate NF-κB, JNK/SAPK, and MAPK pathways; it also mediates antiviral signaling downstream of MAVS by associating with TRAF3 and recruiting NEMO to activate IRF3 and NF-κB, stabilizes RORγt via K63-linked polyubiquitination to promote Th17 differentiation, suppresses IL-6 receptor signaling by binding gp130 and inhibiting JAK1 trans-phosphorylation, and stabilizes IL-17A-responsive mRNAs through an Act1–TRAF2/TRAF5–SF2(ASF) complex, while its own activity in the RLR/IFN pathway requires the Huwe1 ubiquitin E3 ligase."},"narrative":{"mechanistic_narrative":"TRAF5 is a cytoplasmic RING-finger adaptor and ubiquitin ligase of the TRAF family that couples members of the TNF receptor superfamily to NF-κB, JNK/SAPK, and MAPK signaling [PMID:8663299, PMID:8790348]. It is recruited to the cytoplasmic tails of multiple receptors—LT-βR, CD40, ATAR, CD27, OX40, and CD30—through its TRAF homology (MATH) domain, with paralog-specific peptide-binding selectivity that distinguishes it from TRAF2 and TRAF3 [PMID:8663299, PMID:8790348, PMID:9153189, PMID:9582383, PMID:9488716, PMID:26779844]. Across these receptors TRAF5 functions largely redundantly with TRAF2: double-knockout cells show severely impaired TNF-induced (but not IL-1-induced) NF-κB activation, placing the TRAF2/TRAF5 module upstream of a NIK/TAK1–IKK axis that drives IκB degradation and p65 Ser-536 phosphorylation [PMID:9582383, PMID:11479302, PMID:12842894], while acting as a cytoplasmic scaffold that clusters IKKα, NIK, and IκBα [PMID:12000717]. Genetic studies established non-redundant roles in lymphocyte biology, including CD40-driven B-cell activation, CD27 T-cell costimulation, osteoclastogenesis, and plasmacytoid dendritic cell development [PMID:10449775, PMID:12619928, PMID:31668809]. TRAF5 also acts as a brake on inflammation: it constitutively binds gp130 to suppress STAT3 recruitment and JAK1 transphosphorylation, thereby limiting IL-6-driven Th17 differentiation [PMID:24681564, PMID:29668931], and negatively regulates TLR signaling in B cells by disrupting TAB2–TRAF6 association [PMID:24259503]. Through its RING domain it conjugates K63-linked polyubiquitin to RORγt, stabilizing this Th17 master transcription factor [PMID:26453305], and it participates in IL-17-induced mRNA-stabilizing complexes (Act1–TRAF2/TRAF5–SF2(ASF); TRAF2/TRAF5–HuR) that control CXCL1 and PFKFB3 expression [PMID:21822258, PMID:39944257]. In antiviral immunity TRAF5 acts downstream of dimerized MAVS to recruit NEMO and activate IRF3 and NF-κB, with structural and mutational analysis showing that its TRAF domain lacks two residues required for the full TRAF3-like type I interferon response [PMID:20161788, PMID:23150880]. TRAF5 abundance is itself controlled by ubiquitination, being targeted for K48-linked degradation by Numbl [PMID:22593207]. In vivo, TRAF5 deficiency aggravates atherosclerosis, diet-induced metabolic disease, NAFLD/NASH (via JNK1), colitis, and autoimmune neuroinflammation, defining a broadly protective, anti-inflammatory function [PMID:20651286, PMID:24681564, PMID:27032381, PMID:34348490, PMID:37575027].","teleology":[{"year":1996,"claim":"Established TRAF5 as a new TRAF-family adaptor that physically couples a TNF receptor cytoplasmic tail to NF-κB activation, defining its core signaling role.","evidence":"In vitro binding and Co-IP to LT-βR and CD40, NF-κB reporter and domain-truncation/dominant-negative assays in COS7/HEK293 cells (two independent labs)","pmids":["8663299","8790348"],"confidence":"High","gaps":["Receptor binding shown by overexpression/in vitro assays, not endogenous complexes","Catalytic ubiquitin ligase activity of the RING domain not yet demonstrated"]},{"year":1997,"claim":"Extended the receptor repertoire and showed differential TRAF2 vs TRAF5 usage, indicating non-equivalent functions among paralogs at a shared receptor (ATAR).","evidence":"cDNA cloning/chromosomal mapping, in vitro binding and synergistic NF-κB reporter assays","pmids":["9177772","9153189"],"confidence":"Medium","gaps":["Synergy inferred from overexpression, not endogenous signaling","Molecular basis of TRAF2/TRAF5 divergence at ATAR unresolved"]},{"year":1998,"claim":"Placed TRAF5 upstream of NIK and demonstrated it transmits both NF-κB and SAPK/JNK signals from multiple costimulatory receptors (CD27, OX40), mapping the receptor motifs required.","evidence":"Cytoplasmic deletion mapping, dominant-negative epistasis, NF-κB EMSA and kinase assays for CD27 and OX40","pmids":["9582383","9488716"],"confidence":"High","gaps":["Dominant-negative approaches do not distinguish TRAF5 from TRAF2 contribution","Direct kinase activation mechanism not defined"]},{"year":1999,"claim":"Genetic knockout revealed TRAF5 is dispensable for bulk NF-κB/JNK activation but required for specific CD40 B-cell and CD27 T-cell costimulatory outcomes, separating redundant from non-redundant functions.","evidence":"TRAF5-/- mice, NF-κB EMSA, JNK assay, flow cytometry, Ig production assays","pmids":["10449775"],"confidence":"High","gaps":["Residual signaling attributed to redundancy but partner not formally tested here","Molecular events distinguishing affected from unaffected outputs unclear"]},{"year":2001,"claim":"Double-knockout genetics defined TRAF2 and TRAF5 as redundant, pathway-specific mediators of TNF-induced (not IL-1-induced) NF-κB activation and TNF cytoprotection.","evidence":"TRAF2/TRAF5 DKO MEFs, NF-κB nuclear translocation and cytotoxicity assays","pmids":["11479302"],"confidence":"High","gaps":["Does not resolve which proximal receptor complex step requires the TRAFs","Relative contribution of each paralog not quantified"]},{"year":2002,"claim":"Identified a scaffolding role in which TRAF5 nucleates cytoplasmic clusters of IKKα/NIK/IκBα to sustain constitutive NF-κB signaling in malignant cells.","evidence":"Confocal immunofluorescence and dominant-negative rescue in Hodgkin-Reed-Sternberg (CD30) cells","pmids":["12000717"],"confidence":"Medium","gaps":["Co-localization does not prove direct binding to IKK/NIK","Single tumor cell context"]},{"year":2003,"claim":"Positioned the TRAF2/TRAF5 module upstream of TAK1–IKK to drive activating p65 Ser-536 phosphorylation, and revealed signaling-independent requirements for osteoclast differentiation.","evidence":"Phospho-p65 detection in DKO MEFs with siRNA/dominant-negative TAK1/IKK; TRAF5-/- osteoclast cultures and PTH hypercalcemia model","pmids":["12842894","12619928"],"confidence":"High","gaps":["How TRAF5 supports osteoclastogenesis when JNK/NF-κB are intact is undefined","Direct TRAF5–TAK1 contact not shown"]},{"year":2009,"claim":"Refined the DKO phenotype, showing TRAF2/TRAF5 normally restrain basal NIK/IKK activity and support RIP1 ubiquitination, while distinguishing TRAF2-specific cytoprotective functions.","evidence":"IKK/NIK assays, TNFR1 complex IP, RIP1 ubiquitination and cytotoxicity in DKO MEFs","pmids":["19409903"],"confidence":"High","gaps":["TRAF5-specific contribution to RIP1 ubiquitination not isolated","Mechanism of basal NIK restraint by TRAF5 not detailed"]},{"year":2009,"claim":"Demonstrated TRAF5 is the dominant adaptor exploited by EBV LMP1 to drive pathogenic B-cell JNK signaling in vivo, linking the protein to viral oncoprotein signaling.","evidence":"Co-IP and LMP1/CD40 transgenic mice crossed to TRAF5-KO, JNK assay and in vivo phenotyping","pmids":["19805155"],"confidence":"High","gaps":["Direct LMP1–TRAF5 interface not mapped structurally","Whether TRAF5 mediates only JNK or also other LMP1 outputs unresolved"]},{"year":2010,"claim":"Connected TRAF5 to antiviral innate immunity as a MAVS-dependent effector that recruits NEMO and activates IRF3 and NF-κB.","evidence":"Co-IP, ubiquitination assay, IRF3/NF-κB reporters, MAVS truncation, TRAF5 siRNA","pmids":["20161788"],"confidence":"Medium","gaps":["Functional readouts mainly reporter-based","Ubiquitin linkage type and ligase responsible not defined here"]},{"year":2010,"claim":"Established a TRAF2-independent protective, anti-inflammatory role for TRAF5 in vascular disease, restraining leukocyte adhesion, JNK activation, and foam cell formation.","evidence":"TRAF5/LDLR DKO mice, intravital microscopy, adhesion and lipid uptake assays","pmids":["20651286"],"confidence":"High","gaps":["Molecular target of TRAF5's JNK suppression in endothelium/macrophages not identified","Receptor driving the phenotype not pinpointed"]},{"year":2011,"claim":"Defined a post-transcriptional function for TRAF5 in IL-17 signaling, acting in an Act1–TRAF2/TRAF5–SF2(ASF) complex to stabilize chemokine mRNA.","evidence":"siRNA epistasis, mRNA half-life measurement, Co-IP and RNA-protein binding for CXCL1","pmids":["21822258"],"confidence":"High","gaps":["Direct RNA contact by TRAF5 vs scaffold role not separated","Whether ubiquitin ligase activity is involved unknown"]},{"year":2012,"claim":"Provided the structural basis for paralog-specific antiviral output, showing two TRAF3 residues absent in TRAF5 dictate Cardif/MAVS binding and IFN induction; and identified Numbl-mediated K48 ubiquitination as a degradative control of TRAF5.","evidence":"X-ray crystallography of TRAF5/TRAF3 TRAF domains with gain-of-function mutagenesis; Co-IP and K48-ubiquitination/proteasome assays for Numbl","pmids":["23150880","22593207"],"confidence":"High","gaps":["Endogenous consequences of the TRAF5 residue differences not tested in vivo","Whether Numbl regulation occurs physiologically beyond glioma cells unclear"]},{"year":2013,"claim":"Revealed TRAF5 as a negative regulator of TLR/MyD88 signaling in B cells, dampening ERK/JNK and cytokine output by disrupting TAB2–TRAF6 association.","evidence":"TRAF5-KO B cells, cytokine ELISA, phospho-MAPK westerns, Co-IP with MyD88/TAB2/TRAF6","pmids":["24259503"],"confidence":"High","gaps":["Mechanism of selective ERK/JNK control without NF-κB effect unexplained","Cell-type restriction of the negative regulation not fully mapped"]},{"year":2014,"claim":"Identified a constitutive TRAF5–gp130 interaction that suppresses STAT3 to limit Th17 differentiation, establishing TRAF5 as a negative regulator of IL-6 signaling with in vivo autoimmune consequences.","evidence":"Co-IP, STAT3 phosphorylation assay, Traf5-/- Th17 differentiation and EAE model","pmids":["24681564"],"confidence":"High","gaps":["Exact gp130 region competed with STAT3 not residue-mapped","Relationship to TRAF5's positive RORγt-stabilizing role within the same lineage not reconciled here"]},{"year":2015,"claim":"Demonstrated TRAF5 RING-dependent K63 polyubiquitination stabilizes RORγt, providing a positive, enzymatic mechanism promoting Th17 gene expression.","evidence":"Co-IP, K63-specific ubiquitination, RING mutant, TRAF5 knockdown and RORγt stability/qRT-PCR in Th17 cells","pmids":["26453305"],"confidence":"High","gaps":["How this pro-Th17 activity is balanced against TRAF5's anti-Th17 gp130 role unresolved","In vivo requirement of the RING activity for Th17 responses not tested"]},{"year":2016,"claim":"Established isoform-specific JNK1 inhibition as a mechanism by which TRAF5 protects against metabolic liver disease, and confirmed distinct TRAF5 peptide-binding selectivity among paralogs.","evidence":"Traf5-KO×Jnk1-KO epistasis in HFD/ob-ob mice; deep mutational scanning of MATH-domain peptide binding","pmids":["27032381","26779844"],"confidence":"High","gaps":["Direct TRAF5–JNK1 molecular interaction not shown","Functional consequences of the distinct peptide preferences not tested"]},{"year":2018,"claim":"Provided a proximal mechanism for IL-6 suppression, showing constitutive TRAF2/TRAF5 binding to gp130 limits JAK1–JAK1 proximity and transphosphorylation.","evidence":"Luciferase fragment complementation for JAK1–JAK1 proximity and phospho-JAK1 in Traf5-/- T cells","pmids":["29668931"],"confidence":"Medium","gaps":["Proximity assay is indirect for endogenous receptor geometry","Single lab; structural basis of JAK1 separation undefined"]},{"year":2019,"claim":"Defined a cell-intrinsic developmental role for TRAF5 in plasmacytoid dendritic cell commitment via TCF4/ID2 balance.","evidence":"TRAF5-/- mice, bone marrow chimeras, DC subset flow cytometry, progenitor cultures","pmids":["31668809"],"confidence":"Medium","gaps":["Signaling pathway linking TRAF5 to TCF4/ID2 not defined","Single lab"]},{"year":2020,"claim":"Broadened TRAF5's protective, anti-inflammatory functions across tissues (cardiac I/R via AKT, adipocyte inflammation, intestinal TRAF2 protein stabilization, IL-17A-induced IL-6 modulation via 14-3-3ζ).","evidence":"Multiple TRAF5-KO mouse models with AKT phosphorylation, cytokine, proteasome-dependent TRAF2 stability, and Co-IP assays","pmids":["32234528","34348490","32156688","32968020"],"confidence":"Medium","gaps":["Mechanisms linking TRAF5 to AKT and to TRAF2 stabilization not molecularly resolved","Each finding from a single lab/model"]},{"year":2021,"claim":"Implicated TRAF5–LTBR signaling in tumor cell survival, where TRAF5 sustains NF-κB and suppresses necroptosis in hepatocellular carcinoma.","evidence":"Co-IP, siRNA with LTBR overexpression rescue, NF-κB and necroptosis markers, xenograft","pmids":["37366426"],"confidence":"Medium","gaps":["Single tumor context","Direct effect on RIP1/MLKL not mechanistically dissected"]},{"year":2023,"claim":"Linked TRAF5 to control of pathogenic intestinal Th1/Th17 differentiation through Runx1, expanding its T-cell-intrinsic regulatory functions in colitis.","evidence":"T-cell transfer colitis with AAV-mediated Runx1 KO epistasis, flow cytometry, cytokine measurement","pmids":["37575027"],"confidence":"Medium","gaps":["Molecular connection between TRAF5 and Runx1 unknown","Single in vivo model"]},{"year":2024,"claim":"Extended TRAF5's post-transcriptional adaptor role to metabolic reprogramming, forming a TRAF2/TRAF5/HuR complex that stabilizes PFKFB3 mRNA to drive IL-17A-induced glycolysis.","evidence":"Co-IP, RIP, RNA pull-down, siRNA and glycolysis (ECAR) assays in hepatic stellate cells","pmids":["39944257"],"confidence":"Medium","gaps":["Whether TRAF5 binds RNA directly or scaffolds HuR unclear","Single lab/cell type"]},{"year":2025,"claim":"Began to define how TRAF5's antiviral activity is enabled, identifying the E3 ligase Huwe1 as a partner required for TRAF5-driven type I IFN induction.","evidence":"CRISPR Huwe1 KO, IFN-β reporter, proteomics and Co-IP in primary macrophages (preprint)","pmids":["bio_10.1101_2025.03.27.645708"],"confidence":"Low","gaps":["Preprint, single lab, not peer-reviewed","Whether Huwe1 ubiquitinates TRAF5 directly and the linkage type not established","Functional role of TRAF5 as Huwe1 substrate vs cofactor unresolved"]},{"year":null,"claim":"How TRAF5 reconciles its opposing roles—positive RING-dependent stabilization of RORγt versus negative suppression of gp130/STAT3 and TLR/TRAF6 signaling—within the same cell, and what governs the choice between K63-activating and degradative regulation, remains unresolved.","evidence":"","pmids":[],"confidence":"Low","gaps":["No unified model integrating TRAF5's positive and negative immune functions","Endogenous substrate spectrum of TRAF5 ligase activity undefined","Structural basis of receptor-specific recruitment in cells not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[22,18]},{"term_id":"GO:0016874","term_label":"ligase activity","supporting_discovery_ids":[22]},{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[0,1,5,17,33]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[21,25,20]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[10]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[0,10]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[0,4,5,8,11]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,15,20,21,22]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[17,33]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[14,31]}],"complexes":["Act1–TRAF2/TRAF5–SF2(ASF) mRNA-stabilizing complex","TRAF2/TRAF5/HuR complex"],"partners":["TRAF2","TRAF3","MAVS","GP130","RORC","TRAF6","HUWE1","LTBR"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"O00463","full_name":"TNF receptor-associated factor 5","aliases":["RING finger protein 84"],"length_aa":557,"mass_kda":64.4,"function":"Adapter protein and signal transducer that links members of the tumor necrosis factor receptor family to different signaling pathways by association with the receptor cytoplasmic domain and kinases. Mediates activation of NF-kappa-B and probably JNK. Seems to be involved in apoptosis. Plays a role in mediating activation of NF-kappa-B by EIF2AK2/PKR","subcellular_location":"Cytoplasm; Cytoplasm, cytosol","url":"https://www.uniprot.org/uniprotkb/O00463/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/TRAF5","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/TRAF5","total_profiled":1310},"omim":[{"mim_id":"608321","title":"TIR DOMAIN-CONTAINING ADAPTOR MOLECULE 2; TICAM2","url":"https://www.omim.org/entry/608321"},{"mim_id":"606122","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 19; TNFRSF19","url":"https://www.omim.org/entry/606122"},{"mim_id":"605764","title":"TYROSYL-DNA PHOSPHODIESTERASE 2; TDP2","url":"https://www.omim.org/entry/605764"},{"mim_id":"604736","title":"UBIQUITIN-SPECIFIC PROTEASE 25; USP25","url":"https://www.omim.org/entry/604736"},{"mim_id":"603366","title":"TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 25; TNFRSF25","url":"https://www.omim.org/entry/603366"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Centrosome","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in many","driving_tissues":[],"url":"https://www.proteinatlas.org/search/TRAF5"},"hgnc":{"alias_symbol":["RNF84"],"prev_symbol":[]},"alphafold":{"accession":"O00463","domains":[{"cath_id":"3.30.40.10","chopping":"42-131","consensus_level":"high","plddt":92.5419,"start":42,"end":131},{"cath_id":"2.60.210.10","chopping":"401-550","consensus_level":"high","plddt":95.5944,"start":401,"end":550}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/O00463","model_url":"https://alphafold.ebi.ac.uk/files/AF-O00463-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-O00463-F1-predicted_aligned_error_v6.png","plddt_mean":86.94},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=TRAF5","jax_strain_url":"https://www.jax.org/strain/search?query=TRAF5"},"sequence":{"accession":"O00463","fasta_url":"https://rest.uniprot.org/uniprotkb/O00463.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/O00463/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/O00463"}},"corpus_meta":[{"pmid":"12842894","id":"PMC_12842894","title":"Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12842894","citation_count":326,"is_preprint":false},{"pmid":"8663299","id":"PMC_8663299","title":"TRAF5, an activator of NF-kappaB and putative signal transducer for the lymphotoxin-beta receptor.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8663299","citation_count":304,"is_preprint":false},{"pmid":"8790348","id":"PMC_8790348","title":"TRAF5, a novel tumor necrosis factor receptor-associated factor family protein, mediates CD40 signaling.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8790348","citation_count":303,"is_preprint":false},{"pmid":"11479302","id":"PMC_11479302","title":"Critical roles of TRAF2 and TRAF5 in tumor necrosis factor-induced NF-kappa B activation and protection from cell death.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11479302","citation_count":256,"is_preprint":false},{"pmid":"9582383","id":"PMC_9582383","title":"CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9582383","citation_count":216,"is_preprint":false},{"pmid":"21822258","id":"PMC_21822258","title":"Treatment with IL-17 prolongs the half-life of chemokine CXCL1 mRNA via the adaptor TRAF5 and the splicing-regulatory factor SF2 (ASF).","date":"2011","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21822258","citation_count":203,"is_preprint":false},{"pmid":"9488716","id":"PMC_9488716","title":"Activation of OX40 signal transduction pathways leads to tumor necrosis factor receptor-associated factor (TRAF) 2- and TRAF5-mediated NF-kappaB activation.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9488716","citation_count":165,"is_preprint":false},{"pmid":"10449775","id":"PMC_10449775","title":"Targeted disruption of Traf5 gene causes defects in CD40- and CD27-mediated lymphocyte activation.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10449775","citation_count":152,"is_preprint":false},{"pmid":"9153189","id":"PMC_9153189","title":"ATAR, a novel tumor necrosis factor receptor family member, signals through TRAF2 and TRAF5.","date":"1997","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9153189","citation_count":148,"is_preprint":false},{"pmid":"22017431","id":"PMC_22017431","title":"Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions.","date":"2011","source":"Immunological reviews","url":"https://pubmed.ncbi.nlm.nih.gov/22017431","citation_count":90,"is_preprint":false},{"pmid":"33555197","id":"PMC_33555197","title":"Tumor-Associated Macrophages Promote Oxaliplatin Resistance via METTL3-Mediated m6A of TRAF5 and Necroptosis in Colorectal Cancer.","date":"2021","source":"Molecular pharmaceutics","url":"https://pubmed.ncbi.nlm.nih.gov/33555197","citation_count":90,"is_preprint":false},{"pmid":"31078266","id":"PMC_31078266","title":"MiR-141-3p inhibits cell proliferation, migration and invasion by targeting TRAF5 in colorectal cancer.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31078266","citation_count":73,"is_preprint":false},{"pmid":"30233141","id":"PMC_30233141","title":"Astragaloside IV/lncRNA-TUG1/TRAF5 signaling pathway participates in podocyte apoptosis of diabetic nephropathy rats.","date":"2018","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30233141","citation_count":70,"is_preprint":false},{"pmid":"22593207","id":"PMC_22593207","title":"Numbl inhibits glioma cell migration and invasion by suppressing TRAF5-mediated NF-κB activation.","date":"2012","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/22593207","citation_count":70,"is_preprint":false},{"pmid":"20161788","id":"PMC_20161788","title":"TRAF5 is a downstream target of MAVS in antiviral innate immune signaling.","date":"2010","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/20161788","citation_count":70,"is_preprint":false},{"pmid":"17633015","id":"PMC_17633015","title":"Physiological roles and mechanisms of signaling by TRAF2 and TRAF5.","date":"2007","source":"Advances in experimental medicine and biology","url":"https://pubmed.ncbi.nlm.nih.gov/17633015","citation_count":66,"is_preprint":false},{"pmid":"12000717","id":"PMC_12000717","title":"Cytoplasmic aggregation of TRAF2 and TRAF5 proteins in the Hodgkin-Reed-Sternberg cells.","date":"2002","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12000717","citation_count":52,"is_preprint":false},{"pmid":"12619928","id":"PMC_12619928","title":"TRAF5 functions in both RANKL- and TNFalpha-induced osteoclastogenesis.","date":"2003","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/12619928","citation_count":52,"is_preprint":false},{"pmid":"20651286","id":"PMC_20651286","title":"TRAF5 deficiency accelerates atherogenesis in mice by increasing inflammatory cell recruitment and foam cell formation.","date":"2010","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/20651286","citation_count":49,"is_preprint":false},{"pmid":"24259503","id":"PMC_24259503","title":"TRAF5 negatively regulates TLR signaling in B lymphocytes.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/24259503","citation_count":47,"is_preprint":false},{"pmid":"27032381","id":"PMC_27032381","title":"Tumor necrosis factor receptor-associated factor 5 (Traf5) acts as an essential negative regulator of hepatic steatosis.","date":"2016","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/27032381","citation_count":45,"is_preprint":false},{"pmid":"26453305","id":"PMC_26453305","title":"TRAF5-mediated Lys-63-linked Polyubiquitination Plays an Essential Role in Positive Regulation of RORγt in Promoting IL-17A Expression.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26453305","citation_count":43,"is_preprint":false},{"pmid":"31656043","id":"PMC_31656043","title":"LINC00467 promotes cell proliferation and metastasis by binding with IGF2BP3 to enhance the mRNA stability of TRAF5 in hepatocellular carcinoma.","date":"2020","source":"The journal of gene medicine","url":"https://pubmed.ncbi.nlm.nih.gov/31656043","citation_count":40,"is_preprint":false},{"pmid":"24681564","id":"PMC_24681564","title":"The adaptor TRAF5 limits the differentiation of inflammatory CD4(+) T cells by antagonizing signaling via the receptor for IL-6.","date":"2014","source":"Nature immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24681564","citation_count":39,"is_preprint":false},{"pmid":"23774506","id":"PMC_23774506","title":"HIV-1 Nef interacts with HCV Core, recruits TRAF2, TRAF5 and TRAF6, and stimulates HIV-1 replication in macrophages.","date":"2013","source":"Journal of innate immunity","url":"https://pubmed.ncbi.nlm.nih.gov/23774506","citation_count":38,"is_preprint":false},{"pmid":"29792879","id":"PMC_29792879","title":"Astragaloside suppresses apoptosis of the podocytes in rats with diabetic nephropathy via miR-378/TRAF5 signaling pathway.","date":"2018","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/29792879","citation_count":38,"is_preprint":false},{"pmid":"23150880","id":"PMC_23150880","title":"Single amino acid substitutions confer the antiviral activity of the TRAF3 adaptor protein onto TRAF5.","date":"2012","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/23150880","citation_count":37,"is_preprint":false},{"pmid":"26872428","id":"PMC_26872428","title":"MiR-26b inhibits melanoma cell proliferation and enhances apoptosis by suppressing TRAF5-mediated MAPK activation.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26872428","citation_count":34,"is_preprint":false},{"pmid":"19805155","id":"PMC_19805155","title":"TRAF5 is a critical mediator of in vitro signals and in vivo functions of LMP1, the viral oncogenic mimic of CD40.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19805155","citation_count":34,"is_preprint":false},{"pmid":"31011336","id":"PMC_31011336","title":"Upregulation of miR-29b-3p protects cardiomyocytes from hypoxia-induced apoptosis by targeting TRAF5.","date":"2019","source":"Cellular & molecular biology letters","url":"https://pubmed.ncbi.nlm.nih.gov/31011336","citation_count":31,"is_preprint":false},{"pmid":"19409903","id":"PMC_19409903","title":"TRAF2 suppresses basal IKK activity in resting cells and TNFalpha can activate IKK in TRAF2 and TRAF5 double knockout cells.","date":"2009","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/19409903","citation_count":30,"is_preprint":false},{"pmid":"34983361","id":"PMC_34983361","title":"LncRNA HCG18 upregulates TRAF4/TRAF5 to facilitate proliferation, migration and EMT of epithelial ovarian cancer by targeting miR-29a/b.","date":"2022","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/34983361","citation_count":28,"is_preprint":false},{"pmid":"27347306","id":"PMC_27347306","title":"MicroRNA-26b regulates cancer proliferation migration and cell cycle transition by suppressing TRAF5 in esophageal squamous cell carcinoma.","date":"2016","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/27347306","citation_count":27,"is_preprint":false},{"pmid":"30774383","id":"PMC_30774383","title":"miR-135a suppresses migration of gastric cancer cells by targeting TRAF5-mediated NF-κB activation.","date":"2019","source":"OncoTargets and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/30774383","citation_count":27,"is_preprint":false},{"pmid":"24416204","id":"PMC_24416204","title":"TRAF5 and TRAF3IP2 gene polymorphisms are associated with Behçet's disease and Vogt-Koyanagi-Harada syndrome: a case-control study.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24416204","citation_count":26,"is_preprint":false},{"pmid":"29328486","id":"PMC_29328486","title":"miR‑873 inhibits colorectal cancer cell proliferation by targeting TRAF5 and TAB1.","date":"2018","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/29328486","citation_count":26,"is_preprint":false},{"pmid":"33010282","id":"PMC_33010282","title":"Circ_0010729 regulates hypoxia-induced cardiomyocyte injuries by activating TRAF5 via sponging miR-27a-3p.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33010282","citation_count":25,"is_preprint":false},{"pmid":"38840180","id":"PMC_38840180","title":"CD36 deletion prevents white matter injury by modulating microglia polarization through the Traf5-MAPK signal pathway.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/38840180","citation_count":24,"is_preprint":false},{"pmid":"26779844","id":"PMC_26779844","title":"Comparison of the peptide binding preferences of three closely related TRAF paralogs: TRAF2, TRAF3, and TRAF5.","date":"2016","source":"Protein science : a publication of the Protein Society","url":"https://pubmed.ncbi.nlm.nih.gov/26779844","citation_count":23,"is_preprint":false},{"pmid":"23329887","id":"PMC_23329887","title":"Up-regulation and pre-activation of TRAF3 and TRAF5 in inflammatory bowel disease.","date":"2013","source":"International journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/23329887","citation_count":22,"is_preprint":false},{"pmid":"34369042","id":"PMC_34369042","title":"Downregulation of long noncoding RNA SNHG7 protects against inflammation and apoptosis in Parkinson's disease model by targeting the miR-425-5p/TRAF5/NF-κB axis.","date":"2021","source":"Journal of biochemical and molecular toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/34369042","citation_count":22,"is_preprint":false},{"pmid":"32968020","id":"PMC_32968020","title":"14-3-3ζ-TRAF5 axis governs interleukin-17A signaling.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/32968020","citation_count":18,"is_preprint":false},{"pmid":"32976214","id":"PMC_32976214","title":"LncRNA CDKN2B-AS1 contributes to tumorigenesis and chemoresistance in pediatric T-cell acute lymphoblastic leukemia through miR-335-3p/TRAF5 axis.","date":"2020","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/32976214","citation_count":18,"is_preprint":false},{"pmid":"32234528","id":"PMC_32234528","title":"TRAF5 protects against myocardial ischemia reperfusion injury via AKT signaling.","date":"2020","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32234528","citation_count":18,"is_preprint":false},{"pmid":"33048450","id":"PMC_33048450","title":"Down-regulated HDAC3 elevates microRNA-495-3p to restrain epithelial-mesenchymal transition and oncogenicity of melanoma cells via reducing TRAF5.","date":"2020","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33048450","citation_count":17,"is_preprint":false},{"pmid":"37017413","id":"PMC_37017413","title":"PCSK9 inhibitor attenuates atherosclerosis by regulating SNHG16/EZH2/TRAF5-mediated VSMC proliferation, migration, and foam cell formation.","date":"2023","source":"Cell biology international","url":"https://pubmed.ncbi.nlm.nih.gov/37017413","citation_count":16,"is_preprint":false},{"pmid":"11333886","id":"PMC_11333886","title":"Activation of TRAF5 and TRAF6 signal cascades negatively regulates the latent replication origin of Epstein-Barr virus through p38 mitogen-activated protein kinase.","date":"2001","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/11333886","citation_count":15,"is_preprint":false},{"pmid":"9511754","id":"PMC_9511754","title":"Cloning and characterization of a cDNA encoding the human homolog of tumor necrosis factor receptor-associated factor 5 (TRAF5).","date":"1998","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/9511754","citation_count":15,"is_preprint":false},{"pmid":"31722554","id":"PMC_31722554","title":"miR-141-3p and TRAF5 Network Contributes to the Progression of T-Cell Acute Lymphoblastic Leukemia.","date":"2019","source":"Cell transplantation","url":"https://pubmed.ncbi.nlm.nih.gov/31722554","citation_count":14,"is_preprint":false},{"pmid":"9177772","id":"PMC_9177772","title":"Human TNF receptor-associated factor 5 (TRAF5): cDNA cloning, expression and assignment of the TRAF5 gene to chromosome 1q32.","date":"1997","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9177772","citation_count":13,"is_preprint":false},{"pmid":"33752668","id":"PMC_33752668","title":"Silenced lncRNA DDX11-AS1 or up-regulated microRNA-34a-3p inhibits malignant phenotypes of hepatocellular carcinoma cells via suppression of TRAF5.","date":"2021","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/33752668","citation_count":12,"is_preprint":false},{"pmid":"31696495","id":"PMC_31696495","title":"Overexpression of miRNA-410-3p protects hypoxia-induced cardiomyocyte injury via targeting TRAF5.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31696495","citation_count":11,"is_preprint":false},{"pmid":"34348490","id":"PMC_34348490","title":"Genetic Deficiency of TRAF5 Promotes Adipose Tissue Inflammation and Aggravates Diet-Induced Obesity in Mice.","date":"2021","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/34348490","citation_count":10,"is_preprint":false},{"pmid":"34021268","id":"PMC_34021268","title":"Association of methylation level and transcript level in TRAF5 gene with ankylosing spondylitis: a case-control study.","date":"2021","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/34021268","citation_count":10,"is_preprint":false},{"pmid":"34249436","id":"PMC_34249436","title":"HP1BP3 promotes tumor growth and metastasis by upregulating miR-23a to target TRAF5 in esophageal squamous cell carcinoma.","date":"2021","source":"American journal of cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/34249436","citation_count":10,"is_preprint":false},{"pmid":"29115406","id":"PMC_29115406","title":"Berberine prevents the apoptosis of mouse podocytes induced by TRAF5 overexpression by suppressing NF-κB activation.","date":"2017","source":"International journal of molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/29115406","citation_count":10,"is_preprint":false},{"pmid":"37575027","id":"PMC_37575027","title":"TRAF5 regulates intestinal mucosal Th1/Th17 cell immune responses via Runx1 in colitis mice.","date":"2023","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37575027","citation_count":9,"is_preprint":false},{"pmid":"35116901","id":"PMC_35116901","title":"Effects of antisense lncRNA PCBP1-AS1 on biological behaviors of vulvar squamous carcinoma cells by regulating TRAF5 and NF-κB expression.","date":"2019","source":"Translational cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/35116901","citation_count":9,"is_preprint":false},{"pmid":"29668931","id":"PMC_29668931","title":"TRAF2 and TRAF5 associated with the signal transducing receptor gp130 limit IL-6-driven transphosphorylation of JAK1 through the inhibition of proximal JAK-JAK interaction.","date":"2018","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29668931","citation_count":7,"is_preprint":false},{"pmid":"34062236","id":"PMC_34062236","title":"Grouper TRAF5 exerts negative regulation on antiviral immune response against iridovirus.","date":"2021","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/34062236","citation_count":7,"is_preprint":false},{"pmid":"36152803","id":"PMC_36152803","title":"TRAF5 splicing variants associate with TRAF3 and RIP1 in NF-κB and type I IFN signaling in large yellow croaker Larimichthys crocea.","date":"2022","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36152803","citation_count":6,"is_preprint":false},{"pmid":"37366426","id":"PMC_37366426","title":"Silencing of TRAF5 enhances necroptosis in hepatocellular carcinoma by inhibiting LTBR-mediated NF-κB signaling.","date":"2023","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/37366426","citation_count":6,"is_preprint":false},{"pmid":"32911926","id":"PMC_32911926","title":"TRAF5 promotes the occurrence and development of colon cancer via the activation of PI3K/AKT/NF-κB signaling pathways.","date":"2020","source":"Journal of biological regulators and homeostatic agents","url":"https://pubmed.ncbi.nlm.nih.gov/32911926","citation_count":6,"is_preprint":false},{"pmid":"32518521","id":"PMC_32518521","title":"The fiber metabolite butyrate reduces gp130 by targeting TRAF5 in colorectal cancer cells.","date":"2020","source":"Cancer cell international","url":"https://pubmed.ncbi.nlm.nih.gov/32518521","citation_count":6,"is_preprint":false},{"pmid":"38088510","id":"PMC_38088510","title":"METTL3-mediated m6 A methylation of TRAF5 inhibits lung adenocarcinoma cell metastasis via activation of the PI3K/AKT/NF-κB signaling pathway.","date":"2023","source":"The Kaohsiung journal of medical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38088510","citation_count":5,"is_preprint":false},{"pmid":"33997937","id":"PMC_33997937","title":"Single nucleotide polymorphisms of TRAF2 and TRAF5 gene in ankylosing spondylitis: a case-control study.","date":"2021","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33997937","citation_count":5,"is_preprint":false},{"pmid":"26454171","id":"PMC_26454171","title":"Retinoic acid-inducible gene-I-like receptor (RLR)-mediated antiviral innate immune responses in the lower respiratory tract: Roles of TRAF3 and TRAF5.","date":"2015","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26454171","citation_count":5,"is_preprint":false},{"pmid":"40003916","id":"PMC_40003916","title":"Exploring the Anti-Colorectal Cancer Mechanism of Norcantharidin Through TRAF5/NF-κB Pathway Regulation and Folate-Targeted Liposomal Delivery.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/40003916","citation_count":4,"is_preprint":false},{"pmid":"32283248","id":"PMC_32283248","title":"Structural and biochemical characterization of TRAF5 from Notothenia coriiceps and its implications in fish immune cell signaling.","date":"2020","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/32283248","citation_count":4,"is_preprint":false},{"pmid":"37330462","id":"PMC_37330462","title":"Identification of necroptosis-related gene TRAF5 as potential target of diagnosing atherosclerosis and assessing its stability.","date":"2023","source":"BMC medical genomics","url":"https://pubmed.ncbi.nlm.nih.gov/37330462","citation_count":3,"is_preprint":false},{"pmid":"31668809","id":"PMC_31668809","title":"TRAF5 promotes plasmacytoid dendritic cell development from bone marrow progenitors.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31668809","citation_count":3,"is_preprint":false},{"pmid":"32156688","id":"PMC_32156688","title":"TRAF5 Deficiency Ameliorates the Severity of Dextran Sulfate Sodium Colitis by Decreasing TRAF2 Expression in Nonhematopoietic Cells.","date":"2020","source":"ImmunoHorizons","url":"https://pubmed.ncbi.nlm.nih.gov/32156688","citation_count":3,"is_preprint":false},{"pmid":"39944257","id":"PMC_39944257","title":"Interleukin 17A promotes glycolysis to activate human hepatic stellate cells by mediating the TRAF2/TRAF5/HuR/PFKFB3 axis.","date":"2024","source":"Central-European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39944257","citation_count":3,"is_preprint":false},{"pmid":"40093618","id":"PMC_40093618","title":"Lithocholic acid attenuates DON-induced inflammatory responses via epigenetic regulation of DUSP5 and TRAF5 in porcine intestinal epithelial cells.","date":"2025","source":"Frontiers in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/40093618","citation_count":2,"is_preprint":false},{"pmid":"41196309","id":"PMC_41196309","title":"PGC1α alleviates M1 macrophage polarization through dual regulation of succinate metabolism and TRAF5 expression to mitigate TLR4/NF-κB-driven inflammatory cascades and myocardial ischemia/reperfusion injury.","date":"2025","source":"Inflammation research : official journal of the European Histamine Research Society ... [et al.]","url":"https://pubmed.ncbi.nlm.nih.gov/41196309","citation_count":1,"is_preprint":false},{"pmid":"41658503","id":"PMC_41658503","title":"Rare TRAF5 coding variants in systemic lupus erythematosus patients aggravate pulmonary hypertension via endothelial dysfunction.","date":"2025","source":"Innovation (Cambridge (Mass.))","url":"https://pubmed.ncbi.nlm.nih.gov/41658503","citation_count":0,"is_preprint":false},{"pmid":"40191236","id":"PMC_40191236","title":"MicroRNA-18b-5p Inhibits the Malignant Progression of Prostate Cancer Through Downregulating TRAF5.","date":"2025","source":"International journal of general medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40191236","citation_count":0,"is_preprint":false},{"pmid":"41096757","id":"PMC_41096757","title":"Defective IgG Class Switching in the Spleen of TRAF5-Deficient Mice Reveals a Role for TRAF5 in CD40-Mediated B Cell Responses During Obesity-Associated Inflammation.","date":"2025","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/41096757","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.03.27.645708","title":"The ubiquitin E3 ligase Huwe1 facilitates viral and self RNA sensing by RIG-I-like receptors","date":"2025-04-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.27.645708","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":43651,"output_tokens":9479,"usd":0.136569,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19642,"output_tokens":7791,"usd":0.146492,"stage2_stop_reason":"end_turn"},"total_usd":0.283061,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1996,\n      \"finding\": \"TRAF5 was identified as a novel TRAF family member containing RING finger, zinc finger, coiled-coil, and TRAF homology domains. In vitro translation and co-immunoprecipitation in COS7 cells showed TRAF5 binds the cytoplasmic region of the lymphotoxin-beta receptor (LT-βR) but not CD40, both TNF receptors, Fas, or NGF receptor. Overexpression of full-length TRAF5 (but not a truncated form lacking the zinc-binding region) activated NF-κB in HEK293 cells, and dominant-negative TRAF5 partially inhibited LT-βR-induced NF-κB activation.\",\n      \"method\": \"In vitro binding assay (translated protein), co-immunoprecipitation in COS7 cells, NF-κB reporter assay in HEK293 cells, domain truncation analysis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — multiple orthogonal methods (in vitro binding, Co-IP, reporter assay, domain mutagenesis), foundational paper replicated by subsequent work\",\n      \"pmids\": [\"8663299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"TRAF5 was cloned via yeast two-hybrid using the CD40 cytoplasmic tail as bait. In vitro binding assays confirmed TRAF5 associates with CD40 (residues 230–269 required) but not TNFR2. Overexpression of TRAF5 activates NF-κB, and amino-terminally truncated TRAF5 suppresses CD40-mediated CD23 induction, similar to TRAF3.\",\n      \"method\": \"Yeast two-hybrid, in vitro binding assay, NF-κB reporter assay, CD40 deletion mutant analysis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — yeast two-hybrid plus in vitro binding plus functional reporter, corroborated by independent lab (PMID 8663299)\",\n      \"pmids\": [\"8790348\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"Human TRAF5 cDNA was cloned and mapped to chromosome 1q32. The encoded 557-aa protein retains typical TRAF family structural features. Overexpression of human TRAF5 activated NF-κB in 293T cells, and the protein was found to bind LT-βR cytoplasmic region more efficiently than CD40 or CD30.\",\n      \"method\": \"cDNA cloning, chromosomal mapping (FISH), NF-κB reporter assay, binding assay\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reporter assay and binding data consistent with founding papers; single lab\",\n      \"pmids\": [\"9177772\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The novel TNFR family member ATAR (both human and mouse) physically interacts with TRAF5 and TRAF2 via its C-terminal 20 amino acids. Co-expression of ATAR with TRAF5 (but not TRAF2) results in synergistic NF-κB activation, indicating differential roles of TRAF2 and TRAF5 downstream of ATAR.\",\n      \"method\": \"In vitro binding assay, co-immunoprecipitation, NF-κB reporter assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and reporter assay, single lab, two complementary methods\",\n      \"pmids\": [\"9153189\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CD27 activates NF-κB and SAPK/JNK through direct interaction with TRAF2 and TRAF5 via its C-terminal PIQEDYR motif. Dominant-negative TRAF2 or TRAF5 blocked both NF-κB and SAPK/JNK activation induced by CD27. NF-κB-inducing kinase (NIK) acts as a common downstream kinase of TRAF2 and TRAF5 in this pathway.\",\n      \"method\": \"Cytoplasmic domain deletion analysis, dominant-negative transfection, NF-κB EMSA, kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — epistasis established by dominant-negatives plus deletion mapping, replicated in multiple cell types, subsequently confirmed by KO mice (PMID 10449775)\",\n      \"pmids\": [\"9582383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"OX40 associates with TRAF1, TRAF2, TRAF3, and TRAF5 (but not TRAF4) in vitro, and with TRAF2, TRAF3, and TRAF5 in vivo. A cytoplasmic sequence (aa 256–263, GGSFRTPI) is required for TRAF association and NF-κB activation. Dominant-negative TRAF2 and TRAF5 suppress OX40-induced NF-κB activation in a dose-dependent manner.\",\n      \"method\": \"GST pull-down, co-immunoprecipitation in HEK293T, NF-κB EMSA, deletion mutant analysis, dominant-negative transfection\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — GST pull-down, reciprocal Co-IP, and functional epistasis with dominant negatives, multiple orthogonal methods\",\n      \"pmids\": [\"9488716\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Human TRAF5 protein binds the LT-βR cytoplasmic region more efficiently than CD40 or CD30, and overexpression activates NF-κB in 293T cells. The gene was mapped to human chromosome 1q32.3–q41.1.\",\n      \"method\": \"cDNA cloning, binding assay, NF-κB reporter assay, chromosomal mapping (PCR-RFLP)\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — binding assay and reporter assay, confirmatory of earlier papers, single lab\",\n      \"pmids\": [\"9511754\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"TRAF5-deficient mice generated by gene targeting showed that TRAF5 loss does not completely abrogate TNF-, CD27-, or CD40-induced NF-κB or JNK activation, but TRAF5-/- B cells exhibit defects in CD40-driven proliferation, upregulation of CD23, CD54, CD80, CD86, and Fas, and reduced IgG production with IL-4. TRAF5-/- T cells show impaired CD27-mediated costimulatory signaling.\",\n      \"method\": \"Gene targeting (KO mice), NF-κB EMSA, JNK kinase assay, flow cytometry, in vitro Ig production assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic KO with multiple defined cellular phenotypes and signaling readouts, replicated across lymphocyte subsets\",\n      \"pmids\": [\"10449775\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"TRAF2 and TRAF5 double knockout (DKO) MEFs show severely impaired TNF-induced (but not IL-1-induced) NF-κB nuclear translocation, establishing redundant roles for TRAF2 and TRAF5 specifically in TNF-induced NF-κB activation. DKO MEFs are more susceptible to TNF-induced cytotoxicity than TRAF2 single KO cells.\",\n      \"method\": \"Double knockout mouse embryonic fibroblasts, NF-κB nuclear translocation assay, cytotoxicity assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis via double KO, multiple signaling and viability readouts, clean mechanistic separation from IL-1 pathway\",\n      \"pmids\": [\"11479302\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Overexpression of TRAF5 (and TRAF6), or LMP1 (via its TRAF-binding site), suppresses Epstein-Barr virus oriP replication through a p38 MAPK-dependent pathway. Dominant-negative TRAF5 and TRAF6 relieve LMP1-induced oriP suppression; p38 MAPK inhibition abolishes the suppressive effect.\",\n      \"method\": \"Transient replication assay, dominant-negative transfection, p38 MAPK inhibitor, LMP1 deletion mutant analysis\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional epistasis with dominant negatives and pharmacological inhibitor, single lab\",\n      \"pmids\": [\"11333886\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"In Hodgkin-Reed-Sternberg (H-RS) cells with constitutively active CD30 signaling, TRAF2 and TRAF5 aggregate in cytoplasmic clusters and co-localize with IKKα, NIK, and IκBα. Dominant-negative TRAF2 and TRAF5 suppressed cytoplasmic aggregation and constitutive NF-κB activation, suggesting TRAF5 functions as a scaffolding protein in CD30-driven NF-κB signaling.\",\n      \"method\": \"Confocal immunofluorescence microscopy, dominant-negative transfection, NF-κB assay\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 / Moderate — direct localization by confocal microscopy with functional consequence (dominant-negative rescue), single lab\",\n      \"pmids\": [\"12000717\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TNF-α-induced phosphorylation of NF-κB p65 on Ser-536 is mediated through a TRAF2/TRAF5–TAK1–IKK pathway. This phosphorylation is severely impaired in MEFs from traf2-/-traf5-/- double KO mice. Dominant-negative TAK1, IKKα, IKKβ, and siRNAs against TAK1, IKKα, IKKβ each blocked the phosphorylation.\",\n      \"method\": \"Anti-phospho-p65 (Ser-536) antibody, double KO MEFs, dominant-negative overexpression, siRNA knockdown\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic (DKO MEFs), siRNA, and dominant-negative approaches in combination; multiple orthogonal methods establishing pathway position\",\n      \"pmids\": [\"12842894\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"TRAF5-deficient osteoclast progenitor cells fail to differentiate effectively into mature multinucleated osteoclasts in response to RANKL or TNFα, even though JNK and NF-κB activation is preserved, demonstrating TRAF5 is required for osteoclastogenesis downstream of or parallel to these signaling events. In vivo, PTH-induced hypercalcemia is delayed in TRAF5-deficient mice.\",\n      \"method\": \"TRAF5-deficient mouse osteoclast progenitor cultures, RANKL/TNFα stimulation, JNK/NF-κB activation assay, PTH hypercalcemia model\",\n      \"journal\": \"Journal of bone and mineral research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO mouse cells with defined osteoclast differentiation phenotype, in vivo PTH model, multiple readouts\",\n      \"pmids\": [\"12619928\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"TRAF5 associates strongly with Epstein-Barr virus latent membrane protein 1 (LMP1) — more strongly than with CD40 — and is required for LMP1-mediated c-Jun kinase signaling and B cell hyperactivation phenotypes. In mice expressing LMP1 in place of CD40, TRAF5 deficiency abrogated much of the abnormal splenic phenotype (splenomegaly, lymphadenopathy, elevated IL-6, autoantibodies).\",\n      \"method\": \"Co-immunoprecipitation, LMP1/CD40 transgenic mice crossed with TRAF5-KO mice, JNK assay, in vivo phenotyping\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vitro Co-IP combined with in vivo genetic epistasis in transgenic/KO mice, multiple phenotypic readouts\",\n      \"pmids\": [\"19805155\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In TRAF2/TRAF5 double KO (T2/5 DKO) cells, basal IKK activity and NF-κB-dependent gene expression are elevated (not reduced) due to elevated NIK activity. TNFα-induced RIP1 ubiquitination is impaired in DKO cells, yet TNFα can still further activate IKK. TRAF2 (not TRAF5) is required for recruiting anti-apoptotic proteins to TNFR1 complex and protecting against TNFα-induced cell death.\",\n      \"method\": \"DKO MEF cells, IKK kinase assay, NF-κB target gene expression, NIK inhibition, TNFR1 complex immunoprecipitation, cytotoxicity assay\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple signaling assays in DKO cells plus rescue experiments; mechanistically refines the DKO phenotype reported by earlier studies\",\n      \"pmids\": [\"19409903\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TRAF5 is a downstream effector of MAVS in antiviral innate immune signaling. The MAVS transmembrane domain mediates dimerization and subsequent association with TRAF5 and induction of TRAF5 ubiquitination in a CARD-dependent manner. TRAF5 mediates both IRF3 and NF-κB activation downstream of MAVS, and NEMO is recruited to dimerized MAVS in a TRAF3/TRAF5-dependent manner.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, IRF3/NF-κB reporter assays, MAVS domain truncation, siRNA knockdown of TRAF5\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination assay, and reporter assays; single lab, multiple complementary methods\",\n      \"pmids\": [\"20161788\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"TRAF5 deficiency in mice accelerates atherosclerosis: TRAF5-/-/LDLR-/- mice develop larger lesions with more lipids and macrophages. TRAF5 deficiency in endothelial cells or leukocytes enhances inflammatory cell adhesion and increases JNK activation, and TRAF5-deficient macrophages show enhanced foam cell formation. These effects appear independent of TRAF2.\",\n      \"method\": \"TRAF5/LDLR double KO mice on high-cholesterol diet, intravital microscopy, dynamic adhesion assays, foam cell lipid uptake assay, JNK activation measurement\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — in vivo KO mouse model with intravital microscopy plus in vitro mechanistic assays, multiple orthogonal methods\",\n      \"pmids\": [\"20651286\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"IL-17 stabilizes CXCL1 mRNA via a pathway involving Act1→TRAF2/TRAF5→SF2(ASF). TRAF2 and TRAF5 are necessary for IL-17-induced mRNA stabilization. IL-17 promotes formation of a TRAF5–TRAF2–Act1–SF2(ASF) complex; SF2(ASF) binding to CXCL1 mRNA is reduced after IL-17 stimulation, correlating with mRNA stabilization.\",\n      \"method\": \"siRNA knockdown, mRNA half-life assay, co-immunoprecipitation, RNA-protein binding assay\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — siRNA epistasis establishing pathway order, Co-IP of complex, mRNA half-life measurement, multiple orthogonal approaches in one study\",\n      \"pmids\": [\"21822258\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Numbl directly interacts with TRAF5 and promotes K48-linked polyubiquitination of TRAF5, committing it to proteasomal degradation, thereby dampening TRAF5-dependent NF-κB activation and inhibiting glioma cell migration and invasion.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (K48-specific), proteasome inhibitor treatment, overexpression/knockdown of Numbl, NF-κB reporter, migration/invasion assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, ubiquitination linkage characterization, and functional rescue; single lab\",\n      \"pmids\": [\"22593207\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Crystal structures of the TRAF domain of TRAF5 and TRAF3 (bound to a Cardif/MAVS TRAF-interacting motif peptide) were solved. Structural comparison identified two key residues in TRAF3 (Tyr440 and Phe473) near the Cardif binding pocket absent in TRAF5. Mutating the corresponding TRAF5 residues to match TRAF3 conferred TRAF3-like antiviral (IFN-inducing) activity on TRAF5.\",\n      \"method\": \"X-ray crystallography, in vitro binding assay, cellular IFN reporter assay, site-directed mutagenesis\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure plus mutagenesis plus functional in vitro and cellular assays; rigorous multi-method single study\",\n      \"pmids\": [\"23150880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"TRAF5 is a negative regulator of TLR signaling in B lymphocytes. TRAF5-/- B cells overproduce IL-6, IL-12p40, IL-10, TNF-α, and IgM upon TLR stimulation, with markedly enhanced phosphorylation of ERK1/2 and JNK but no effect on NF-κB or cell survival. Following TLR stimulation, TRAF5 associates with MyD88 and TAB2, and negatively regulates TAB2–TRAF6 association.\",\n      \"method\": \"TRAF5 KO B cells, cytokine ELISA, flow cytometry, phospho-MAPK western blot, co-immunoprecipitation (TRAF5 with MyD88/TAB2/TRAF6)\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — KO cells with multiple cytokine and signaling readouts, Co-IP establishing molecular mechanism, cell-type specificity confirmed\",\n      \"pmids\": [\"24259503\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"TRAF5 constitutively associates with a cytoplasmic region of gp130 that overlaps the STAT3 binding site, suppressing STAT3 recruitment and activation in response to IL-6, thereby limiting Th17 differentiation. TRAF5-deficient naïve CD4+ T cells show enhanced Th17 differentiation and TH17-driven EAE is greatly exacerbated in Traf5-/- mice.\",\n      \"method\": \"Co-immunoprecipitation (TRAF5–gp130), STAT3 phosphorylation assay, Traf5-/- mouse model, Th17 differentiation assay, EAE model\",\n      \"journal\": \"Nature immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — Co-IP establishing direct gp130 binding, signaling assay, KO mouse with in vivo disease model, multiple orthogonal methods\",\n      \"pmids\": [\"24681564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"TRAF5 directly interacts with RORγt (the Th17 master transcription factor) and promotes K63-linked polyubiquitination of RORγt via its RING finger domain, stabilizing RORγt protein. TRAF5 depletion in Th17 cells destabilizes RORγt and downregulates IL-17A and other Th17-related genes.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay (K63-specific), RING domain mutant, TRAF5 knockdown in Th17 cells, RORγt protein stability assay, qRT-PCR\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — Co-IP, K63-specific ubiquitination, RING domain mutagenesis, and functional gene expression readout; multiple orthogonal methods in one study\",\n      \"pmids\": [\"26453305\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"TRAF5 negatively regulates NAFLD/NASH by blocking JNK1 (but not JNK2) activity. TRAF5 deficiency worsens HFD-induced metabolic disorders, and Jnk1 ablation markedly ameliorates the detrimental effects of Traf5 deficiency on obesity, inflammation, insulin resistance, hepatic steatosis, and fibrosis.\",\n      \"method\": \"TRAF5 KO and overexpression in mice (HFD and ob/ob models), JNK1/JNK2-selective genetic ablation, liver histology, metabolic parameters\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic epistasis (Traf5-KO × Jnk1-KO), multiple in vivo mouse models, isoform specificity established\",\n      \"pmids\": [\"27032381\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Deep mutational scanning of TRAF2, TRAF3, and TRAF5 MATH domain peptide-binding preferences revealed that TRAF5 shows distinct peptide binding specificity compared to TRAF2 and TRAF3. Different preferences were identified in both CD40 and TANK background peptide libraries, demonstrating previously unappreciated binding selectivity among TRAF paralogs.\",\n      \"method\": \"Deep mutational scanning, bacterial surface display of peptide libraries, next-generation sequencing enrichment analysis, individual peptide affinity measurement\",\n      \"journal\": \"Protein science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — rigorous in vitro binding screen with mutagenesis, but functional consequences not tested; single lab\",\n      \"pmids\": [\"26779844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"TRAF2 and TRAF5 constitutively bind to gp130 and inhibit IL-6-driven JAK1 transphosphorylation by limiting proximal JAK1–JAK1 interaction in the IL-6 receptor complex. This was demonstrated using a luciferase fragment complementation system for JAK1–JAK1 proximity. Traf5-/- CD4+ T cells display significantly higher IL-6-induced pJAK1 levels than wild-type cells.\",\n      \"method\": \"Luciferase fragment complementation for JAK1–JAK1 interaction, HEK293T co-transfection, phospho-JAK1 western blot in Traf5-/- T cells\",\n      \"journal\": \"International immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — bioluminescence complementation for protein proximity plus KO cell validation; single lab, two complementary methods\",\n      \"pmids\": [\"29668931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"TRAF5 promotes plasmacytoid dendritic cell (pDC) development from bone marrow progenitors in a cell-intrinsic manner. TRAF5 regulates the balance of transcription factors TCF4 and ID2 to promote pDC versus conventional DC commitment.\",\n      \"method\": \"TRAF5-/- mice, bone marrow chimera experiments, flow cytometry of DC subsets, bone marrow progenitor culture, TCF4/ID2 expression analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — cell-intrinsic KO with bone marrow chimeras and defined transcription factor readout; single lab\",\n      \"pmids\": [\"31668809\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"14-3-3ζ physically interacts with TRAF5 (and TRAF6), and this interaction is increased in the presence of IL-17A. TRAF5 acts as an endogenous suppressor of IL-17A-induced IL-6 production, and 14-3-3ζ counters TRAF5's suppressive effect. 14-3-3ζ interaction with TRAF proteins is required for IL-17A-induced IL-6 levels, while TRAF5 and TRAF6 define distinct branches (IL-6 vs. CXCL-1) of IL-17A signaling.\",\n      \"method\": \"Co-immunoprecipitation, genetically manipulated human and mouse cells, ex vivo and in vivo rat models, IL-6/CXCL-1 production assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP and functional KO/KD experiments in multiple models; single lab\",\n      \"pmids\": [\"32968020\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRAF5 protects against myocardial ischemia/reperfusion injury by promoting AKT activation. TRAF5-knockout mice exhibit heavier heart damage, inflammatory response, and cell death after I/R injury. TRAF5 overexpression in H/R-stimulated cardiomyocytes inhibits inflammation and apoptosis.\",\n      \"method\": \"TRAF5 KO mice (myocardial I/R model), cardiomyocyte overexpression, AKT phosphorylation assay, apoptosis/inflammation readouts\",\n      \"journal\": \"European journal of pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse plus cellular overexpression with AKT signaling readout; single lab\",\n      \"pmids\": [\"32234528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TRAF5 deficiency in nonhematopoietic intestinal epithelial cells reduces TRAF2 protein stability in a proteasome-dependent manner during inflammation, identifying TRAF5 as required for TRAF2 protein maintenance in inflamed colon tissue.\",\n      \"method\": \"TRAF5 KO mice (DSS colitis model), bone marrow chimeras, TRAF2 protein assay, proteasome inhibitor treatment, proinflammatory cytokine stimulation of TRAF5-/- nonhematopoietic cells\",\n      \"journal\": \"ImmunoHorizons\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO + chimeras + in vitro proteasome inhibitor; single lab, multiple methods\",\n      \"pmids\": [\"32156688\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAF5 deficiency in mice aggravates diet-induced obesity and metabolic derangements. TRAF5-deficient adipocytes (but not leukocytes) show increased expression of TNFα, MIP-1α, MCP-1, and RANTES, identifying TRAF5 as an anti-inflammatory regulator in adipocytes.\",\n      \"method\": \"Traf5-/- mice on high-fat diet, flow cytometry of adipose stromal vascular fraction, cell-type-specific gene expression, adipocyte isolation\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KO mouse model with cell-type-specific mechanistic resolution; single lab\",\n      \"pmids\": [\"34348490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"TRAF5 silencing in HCC cells enhances necroptosis by suppressing LTBR (lymphotoxin-beta receptor)-mediated NF-κB signaling. Co-immunoprecipitation confirmed interaction between TRAF5 and LTBR. LTBR overexpression abolished the promotive effect of TRAF5 knockdown on necroptosis and reversed NF-κB suppression.\",\n      \"method\": \"Co-immunoprecipitation (TRAF5–LTBR), siRNA knockdown, LTBR overexpression rescue, NF-κB western blot, necroptosis markers (p-RIP1, p-MLKL), xenograft model\",\n      \"journal\": \"PeerJ\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, genetic rescue, signaling pathway and necroptosis markers; single lab\",\n      \"pmids\": [\"37366426\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRAF5 regulates intestinal Th1/Th17 cell differentiation through Runx1. In a T-cell transfer colitis model, TRAF5-/- CD4+ T cells cause more severe colitis with increased IFN-γ, TNF-α, IL-17a. AAV-mediated Runx1 knockout inhibited TRAF5-/- CD4+ T cell differentiation into Th1 and Th17 cells in vivo, placing Runx1 downstream of TRAF5 in this pathway.\",\n      \"method\": \"T-cell transfer colitis model (Rag2-/- recipients), AAV-mediated Runx1 KO in vivo, flow cytometry, cytokine measurement (ELISA, qRT-PCR, IHC)\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo genetic epistasis (TRAF5-KO + Runx1-KO) with defined T cell phenotype; single lab\",\n      \"pmids\": [\"37575027\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"IL-17A promotes formation of a TRAF2/TRAF5/HuR complex that enhances PFKFB3 mRNA stability and expression, thereby activating glycolysis in hepatic stellate cells. Co-IP, RNA immunoprecipitation, and RNA pull-down confirmed interactions among TRAF2, TRAF5, and HuR in this complex. Silencing TRAF2 or TRAF5 abolished IL-17A-induced PFKFB3 upregulation and glycolysis.\",\n      \"method\": \"Co-immunoprecipitation, RNA immunoprecipitation (RIP), RNA pull-down, siRNA knockdown, glycolysis assay (ECAR), western blot\",\n      \"journal\": \"Central-European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP, RIP, and RNA pull-down establishing complex, functional rescue experiments; single lab\",\n      \"pmids\": [\"39944257\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The E3 ubiquitin ligase Huwe1 is required for TRAF5 activity in type I IFN induction downstream of RIG-I-like receptors. Proteomics identified TRAF5 (and MAVS and other TRAFs) as putative Huwe1 substrates; TRAF5 physically interacts with Huwe1; and Huwe1 is essential for TRAF5-dependent IFN-β induction.\",\n      \"method\": \"CRISPR KO of Huwe1, IFN-β reporter assay, proteomics for substrate identification, co-immunoprecipitation (Huwe1–TRAF5), primary macrophages\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 2 / Weak — Co-IP and functional KO data from preprint, single lab, not yet peer-reviewed\",\n      \"pmids\": [\"bio_10.1101_2025.03.27.645708\"],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"TRAF5 is a cytoplasmic adaptor and E3 ubiquitin ligase that is recruited to multiple TNF receptor superfamily members (LT-βR, CD40, CD27, OX40, TNFR1/2) and to cytokine receptors (gp130/IL-6R), where it acts redundantly with TRAF2 to activate NF-κB, JNK/SAPK, and MAPK pathways; it also mediates antiviral signaling downstream of MAVS by associating with TRAF3 and recruiting NEMO to activate IRF3 and NF-κB, stabilizes RORγt via K63-linked polyubiquitination to promote Th17 differentiation, suppresses IL-6 receptor signaling by binding gp130 and inhibiting JAK1 trans-phosphorylation, and stabilizes IL-17A-responsive mRNAs through an Act1–TRAF2/TRAF5–SF2(ASF) complex, while its own activity in the RLR/IFN pathway requires the Huwe1 ubiquitin E3 ligase.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"TRAF5 is a cytoplasmic RING-finger adaptor and ubiquitin ligase of the TRAF family that couples members of the TNF receptor superfamily to NF-\\u03baB, JNK/SAPK, and MAPK signaling [#0, #1]. It is recruited to the cytoplasmic tails of multiple receptors\\u2014LT-\\u03b2R, CD40, ATAR, CD27, OX40, and CD30\\u2014through its TRAF homology (MATH) domain, with paralog-specific peptide-binding selectivity that distinguishes it from TRAF2 and TRAF3 [#0, #1, #3, #4, #5, #24]. Across these receptors TRAF5 functions largely redundantly with TRAF2: double-knockout cells show severely impaired TNF-induced (but not IL-1-induced) NF-\\u03baB activation, placing the TRAF2/TRAF5 module upstream of a NIK/TAK1\\u2013IKK axis that drives I\\u03baB degradation and p65 Ser-536 phosphorylation [#4, #8, #11], while acting as a cytoplasmic scaffold that clusters IKK\\u03b1, NIK, and I\\u03baB\\u03b1 [#10]. Genetic studies established non-redundant roles in lymphocyte biology, including CD40-driven B-cell activation, CD27 T-cell costimulation, osteoclastogenesis, and plasmacytoid dendritic cell development [#7, #12, #26]. TRAF5 also acts as a brake on inflammation: it constitutively binds gp130 to suppress STAT3 recruitment and JAK1 transphosphorylation, thereby limiting IL-6-driven Th17 differentiation [#21, #25], and negatively regulates TLR signaling in B cells by disrupting TAB2\\u2013TRAF6 association [#20]. Through its RING domain it conjugates K63-linked polyubiquitin to ROR\\u03b3t, stabilizing this Th17 master transcription factor [#22], and it participates in IL-17-induced mRNA-stabilizing complexes (Act1\\u2013TRAF2/TRAF5\\u2013SF2(ASF); TRAF2/TRAF5\\u2013HuR) that control CXCL1 and PFKFB3 expression [#17, #33]. In antiviral immunity TRAF5 acts downstream of dimerized MAVS to recruit NEMO and activate IRF3 and NF-\\u03baB, with structural and mutational analysis showing that its TRAF domain lacks two residues required for the full TRAF3-like type I interferon response [#15, #19]. TRAF5 abundance is itself controlled by ubiquitination, being targeted for K48-linked degradation by Numbl [#18]. In vivo, TRAF5 deficiency aggravates atherosclerosis, diet-induced metabolic disease, NAFLD/NASH (via JNK1), colitis, and autoimmune neuroinflammation, defining a broadly protective, anti-inflammatory function [#16, #21, #23, #30, #32].\",\n  \"teleology\": [\n    {\n      \"year\": 1996,\n      \"claim\": \"Established TRAF5 as a new TRAF-family adaptor that physically couples a TNF receptor cytoplasmic tail to NF-\\u03baB activation, defining its core signaling role.\",\n      \"evidence\": \"In vitro binding and Co-IP to LT-\\u03b2R and CD40, NF-\\u03baB reporter and domain-truncation/dominant-negative assays in COS7/HEK293 cells (two independent labs)\",\n      \"pmids\": [\"8663299\", \"8790348\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor binding shown by overexpression/in vitro assays, not endogenous complexes\", \"Catalytic ubiquitin ligase activity of the RING domain not yet demonstrated\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Extended the receptor repertoire and showed differential TRAF2 vs TRAF5 usage, indicating non-equivalent functions among paralogs at a shared receptor (ATAR).\",\n      \"evidence\": \"cDNA cloning/chromosomal mapping, in vitro binding and synergistic NF-\\u03baB reporter assays\",\n      \"pmids\": [\"9177772\", \"9153189\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Synergy inferred from overexpression, not endogenous signaling\", \"Molecular basis of TRAF2/TRAF5 divergence at ATAR unresolved\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Placed TRAF5 upstream of NIK and demonstrated it transmits both NF-\\u03baB and SAPK/JNK signals from multiple costimulatory receptors (CD27, OX40), mapping the receptor motifs required.\",\n      \"evidence\": \"Cytoplasmic deletion mapping, dominant-negative epistasis, NF-\\u03baB EMSA and kinase assays for CD27 and OX40\",\n      \"pmids\": [\"9582383\", \"9488716\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Dominant-negative approaches do not distinguish TRAF5 from TRAF2 contribution\", \"Direct kinase activation mechanism not defined\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Genetic knockout revealed TRAF5 is dispensable for bulk NF-\\u03baB/JNK activation but required for specific CD40 B-cell and CD27 T-cell costimulatory outcomes, separating redundant from non-redundant functions.\",\n      \"evidence\": \"TRAF5-/- mice, NF-\\u03baB EMSA, JNK assay, flow cytometry, Ig production assays\",\n      \"pmids\": [\"10449775\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Residual signaling attributed to redundancy but partner not formally tested here\", \"Molecular events distinguishing affected from unaffected outputs unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Double-knockout genetics defined TRAF2 and TRAF5 as redundant, pathway-specific mediators of TNF-induced (not IL-1-induced) NF-\\u03baB activation and TNF cytoprotection.\",\n      \"evidence\": \"TRAF2/TRAF5 DKO MEFs, NF-\\u03baB nuclear translocation and cytotoxicity assays\",\n      \"pmids\": [\"11479302\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not resolve which proximal receptor complex step requires the TRAFs\", \"Relative contribution of each paralog not quantified\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identified a scaffolding role in which TRAF5 nucleates cytoplasmic clusters of IKK\\u03b1/NIK/I\\u03baB\\u03b1 to sustain constitutive NF-\\u03baB signaling in malignant cells.\",\n      \"evidence\": \"Confocal immunofluorescence and dominant-negative rescue in Hodgkin-Reed-Sternberg (CD30) cells\",\n      \"pmids\": [\"12000717\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Co-localization does not prove direct binding to IKK/NIK\", \"Single tumor cell context\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Positioned the TRAF2/TRAF5 module upstream of TAK1\\u2013IKK to drive activating p65 Ser-536 phosphorylation, and revealed signaling-independent requirements for osteoclast differentiation.\",\n      \"evidence\": \"Phospho-p65 detection in DKO MEFs with siRNA/dominant-negative TAK1/IKK; TRAF5-/- osteoclast cultures and PTH hypercalcemia model\",\n      \"pmids\": [\"12842894\", \"12619928\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How TRAF5 supports osteoclastogenesis when JNK/NF-\\u03baB are intact is undefined\", \"Direct TRAF5\\u2013TAK1 contact not shown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Refined the DKO phenotype, showing TRAF2/TRAF5 normally restrain basal NIK/IKK activity and support RIP1 ubiquitination, while distinguishing TRAF2-specific cytoprotective functions.\",\n      \"evidence\": \"IKK/NIK assays, TNFR1 complex IP, RIP1 ubiquitination and cytotoxicity in DKO MEFs\",\n      \"pmids\": [\"19409903\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"TRAF5-specific contribution to RIP1 ubiquitination not isolated\", \"Mechanism of basal NIK restraint by TRAF5 not detailed\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrated TRAF5 is the dominant adaptor exploited by EBV LMP1 to drive pathogenic B-cell JNK signaling in vivo, linking the protein to viral oncoprotein signaling.\",\n      \"evidence\": \"Co-IP and LMP1/CD40 transgenic mice crossed to TRAF5-KO, JNK assay and in vivo phenotyping\",\n      \"pmids\": [\"19805155\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct LMP1\\u2013TRAF5 interface not mapped structurally\", \"Whether TRAF5 mediates only JNK or also other LMP1 outputs unresolved\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Connected TRAF5 to antiviral innate immunity as a MAVS-dependent effector that recruits NEMO and activates IRF3 and NF-\\u03baB.\",\n      \"evidence\": \"Co-IP, ubiquitination assay, IRF3/NF-\\u03baB reporters, MAVS truncation, TRAF5 siRNA\",\n      \"pmids\": [\"20161788\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional readouts mainly reporter-based\", \"Ubiquitin linkage type and ligase responsible not defined here\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Established a TRAF2-independent protective, anti-inflammatory role for TRAF5 in vascular disease, restraining leukocyte adhesion, JNK activation, and foam cell formation.\",\n      \"evidence\": \"TRAF5/LDLR DKO mice, intravital microscopy, adhesion and lipid uptake assays\",\n      \"pmids\": [\"20651286\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular target of TRAF5's JNK suppression in endothelium/macrophages not identified\", \"Receptor driving the phenotype not pinpointed\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Defined a post-transcriptional function for TRAF5 in IL-17 signaling, acting in an Act1\\u2013TRAF2/TRAF5\\u2013SF2(ASF) complex to stabilize chemokine mRNA.\",\n      \"evidence\": \"siRNA epistasis, mRNA half-life measurement, Co-IP and RNA-protein binding for CXCL1\",\n      \"pmids\": [\"21822258\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct RNA contact by TRAF5 vs scaffold role not separated\", \"Whether ubiquitin ligase activity is involved unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Provided the structural basis for paralog-specific antiviral output, showing two TRAF3 residues absent in TRAF5 dictate Cardif/MAVS binding and IFN induction; and identified Numbl-mediated K48 ubiquitination as a degradative control of TRAF5.\",\n      \"evidence\": \"X-ray crystallography of TRAF5/TRAF3 TRAF domains with gain-of-function mutagenesis; Co-IP and K48-ubiquitination/proteasome assays for Numbl\",\n      \"pmids\": [\"23150880\", \"22593207\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endogenous consequences of the TRAF5 residue differences not tested in vivo\", \"Whether Numbl regulation occurs physiologically beyond glioma cells unclear\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Revealed TRAF5 as a negative regulator of TLR/MyD88 signaling in B cells, dampening ERK/JNK and cytokine output by disrupting TAB2\\u2013TRAF6 association.\",\n      \"evidence\": \"TRAF5-KO B cells, cytokine ELISA, phospho-MAPK westerns, Co-IP with MyD88/TAB2/TRAF6\",\n      \"pmids\": [\"24259503\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of selective ERK/JNK control without NF-\\u03baB effect unexplained\", \"Cell-type restriction of the negative regulation not fully mapped\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identified a constitutive TRAF5\\u2013gp130 interaction that suppresses STAT3 to limit Th17 differentiation, establishing TRAF5 as a negative regulator of IL-6 signaling with in vivo autoimmune consequences.\",\n      \"evidence\": \"Co-IP, STAT3 phosphorylation assay, Traf5-/- Th17 differentiation and EAE model\",\n      \"pmids\": [\"24681564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Exact gp130 region competed with STAT3 not residue-mapped\", \"Relationship to TRAF5's positive ROR\\u03b3t-stabilizing role within the same lineage not reconciled here\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Demonstrated TRAF5 RING-dependent K63 polyubiquitination stabilizes ROR\\u03b3t, providing a positive, enzymatic mechanism promoting Th17 gene expression.\",\n      \"evidence\": \"Co-IP, K63-specific ubiquitination, RING mutant, TRAF5 knockdown and ROR\\u03b3t stability/qRT-PCR in Th17 cells\",\n      \"pmids\": [\"26453305\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How this pro-Th17 activity is balanced against TRAF5's anti-Th17 gp130 role unresolved\", \"In vivo requirement of the RING activity for Th17 responses not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established isoform-specific JNK1 inhibition as a mechanism by which TRAF5 protects against metabolic liver disease, and confirmed distinct TRAF5 peptide-binding selectivity among paralogs.\",\n      \"evidence\": \"Traf5-KO\\u00d7Jnk1-KO epistasis in HFD/ob-ob mice; deep mutational scanning of MATH-domain peptide binding\",\n      \"pmids\": [\"27032381\", \"26779844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct TRAF5\\u2013JNK1 molecular interaction not shown\", \"Functional consequences of the distinct peptide preferences not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Provided a proximal mechanism for IL-6 suppression, showing constitutive TRAF2/TRAF5 binding to gp130 limits JAK1\\u2013JAK1 proximity and transphosphorylation.\",\n      \"evidence\": \"Luciferase fragment complementation for JAK1\\u2013JAK1 proximity and phospho-JAK1 in Traf5-/- T cells\",\n      \"pmids\": [\"29668931\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Proximity assay is indirect for endogenous receptor geometry\", \"Single lab; structural basis of JAK1 separation undefined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a cell-intrinsic developmental role for TRAF5 in plasmacytoid dendritic cell commitment via TCF4/ID2 balance.\",\n      \"evidence\": \"TRAF5-/- mice, bone marrow chimeras, DC subset flow cytometry, progenitor cultures\",\n      \"pmids\": [\"31668809\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Signaling pathway linking TRAF5 to TCF4/ID2 not defined\", \"Single lab\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Broadened TRAF5's protective, anti-inflammatory functions across tissues (cardiac I/R via AKT, adipocyte inflammation, intestinal TRAF2 protein stabilization, IL-17A-induced IL-6 modulation via 14-3-3\\u03b6).\",\n      \"evidence\": \"Multiple TRAF5-KO mouse models with AKT phosphorylation, cytokine, proteasome-dependent TRAF2 stability, and Co-IP assays\",\n      \"pmids\": [\"32234528\", \"34348490\", \"32156688\", \"32968020\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanisms linking TRAF5 to AKT and to TRAF2 stabilization not molecularly resolved\", \"Each finding from a single lab/model\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Implicated TRAF5\\u2013LTBR signaling in tumor cell survival, where TRAF5 sustains NF-\\u03baB and suppresses necroptosis in hepatocellular carcinoma.\",\n      \"evidence\": \"Co-IP, siRNA with LTBR overexpression rescue, NF-\\u03baB and necroptosis markers, xenograft\",\n      \"pmids\": [\"37366426\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single tumor context\", \"Direct effect on RIP1/MLKL not mechanistically dissected\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked TRAF5 to control of pathogenic intestinal Th1/Th17 differentiation through Runx1, expanding its T-cell-intrinsic regulatory functions in colitis.\",\n      \"evidence\": \"T-cell transfer colitis with AAV-mediated Runx1 KO epistasis, flow cytometry, cytokine measurement\",\n      \"pmids\": [\"37575027\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular connection between TRAF5 and Runx1 unknown\", \"Single in vivo model\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Extended TRAF5's post-transcriptional adaptor role to metabolic reprogramming, forming a TRAF2/TRAF5/HuR complex that stabilizes PFKFB3 mRNA to drive IL-17A-induced glycolysis.\",\n      \"evidence\": \"Co-IP, RIP, RNA pull-down, siRNA and glycolysis (ECAR) assays in hepatic stellate cells\",\n      \"pmids\": [\"39944257\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether TRAF5 binds RNA directly or scaffolds HuR unclear\", \"Single lab/cell type\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Began to define how TRAF5's antiviral activity is enabled, identifying the E3 ligase Huwe1 as a partner required for TRAF5-driven type I IFN induction.\",\n      \"evidence\": \"CRISPR Huwe1 KO, IFN-\\u03b2 reporter, proteomics and Co-IP in primary macrophages (preprint)\",\n      \"pmids\": [\"bio_10.1101_2025.03.27.645708\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Preprint, single lab, not peer-reviewed\", \"Whether Huwe1 ubiquitinates TRAF5 directly and the linkage type not established\", \"Functional role of TRAF5 as Huwe1 substrate vs cofactor unresolved\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How TRAF5 reconciles its opposing roles\\u2014positive RING-dependent stabilization of ROR\\u03b3t versus negative suppression of gp130/STAT3 and TLR/TRAF6 signaling\\u2014within the same cell, and what governs the choice between K63-activating and degradative regulation, remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No unified model integrating TRAF5's positive and negative immune functions\", \"Endogenous substrate spectrum of TRAF5 ligase activity undefined\", \"Structural basis of receptor-specific recruitment in cells not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [22, 18]},\n      {\"term_id\": \"GO:0016874\", \"supporting_discovery_ids\": [22]},\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [0, 1, 5, 17, 33]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [21, 25, 20]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [10]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 10]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 4, 5, 8, 11]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 15, 20, 21, 22]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [17, 33]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [14, 31]}\n    ],\n    \"complexes\": [\n      \"Act1\\u2013TRAF2/TRAF5\\u2013SF2(ASF) mRNA-stabilizing complex\",\n      \"TRAF2/TRAF5/HuR complex\"\n    ],\n    \"partners\": [\n      \"TRAF2\",\n      \"TRAF3\",\n      \"MAVS\",\n      \"gp130\",\n      \"RORC\",\n      \"TRAF6\",\n      \"HUWE1\",\n      \"LTBR\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":9,"faith_total":9,"faith_pct":100.0}}